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Abstract 
In spite of rigorous dose adjustments by way of therapeutic drug monitoring, a large 
proportion of kidney transplant recipients are unable to achieve the target tacrolimus 
trough concentrations. This is attributed to the narrow therapeutic window of the drug 
(10-15 ng/mL) and large inter-individual variability in pharmacokinetic parameter such 
as clearance. There is a need for development of clinical dosing models that can help 
prospectively predict the dose for an individual, especially in the critical period 
immediately post-transplant. Therefore, we established and quantified the effect of 
clinical and genetic factors on tacrolimus clearance (CL/F) using a large population of 
adult kidney transplant recipients. Tacrolimus troughs (n=11823) from 681 transplant 
recipients over the first 6-months post-transplant were analyzed using non-linear mixed 
effects modeling approach in NONMEM
®
. The troughs were characterized by a steady 
state infusion model. Covariates were analyzed using a forward selection (p<0.0.1) 
backward elimination (p<0.001) approach. We formulated an equation that predicts the 
CL/F of an individual based on the days post-transplant, presence of the highly influential 
CYP3A5*1 genotype, transplant at a steroid sparing center, age and concomitant use of a 
calcium channel blocker at the time of trough collection. The CL/F was seen to decrease 
with increasing days post transplant, transplant at a steroid sparing center and use of a 
calcium channel blocker. Transplant recipients with the CYP3A5*1/*3 and *1/*1 
genotypes had a CL/F that was 70% and 100% higher, respectively, than those with the 
CYP3A5*3/*3 genotype. The dose required in order to achieve a particular target trough 
can be prospectively determined from this equation.  
The above equation was validated in a separate cohort of adult kidney transplant 
recipients. The equation was assessed by predictive performance in 795 transplant 
recipients (n=13,968 troughs) receiving tacrolimus using bias and precision. Assessment 
was done for the initial troughs as well as for all troughs over the entire 6 months. The 
equation has low bias (0.2 ng/ml) and good precision (within ± 20% for a typical trough 
of 10 ng/mL) in predicting initial troughs and could be safely used to predict initial doses. 
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This is critical as an accurate initial dose will help the recipient to get to therapeutic range 
faster and reduce the number of out-of-range troughs. For all the troughs, over the 6 
months post-transplant, the equation did better than a basic model with no covariates but 
had higher bias and imprecision than the prediction of initial troughs.  
We were presented with 119 single nucleotide polymorphisms (SNP) in this study. Due 
to software limitations and impracticalities associated with such a large number of 
covariates, we developed and validated a novel “winnowing method” of covariate 
selection that is able to test and select SNPs in combination. This method uses random 
selection, repetitions of generalized additive modeling in the R statistical package and 
post-hoc estimates from NONMEM
®
. The salient feature of this method is the creation of 
an index, ranging from 0-1, that defines the relative importance of the SNP when tested 
in a combination. With this method, we were able to select 26 SNPs out of the 119 SNPs, 
which included the well-established CYP3A5*1 SNP. We validated this method using a 
simulated dataset. In the validation dataset, the winnowing method was able to select all 
the important SNPs. The type I and type II error rates were 9% and 0% respectively.  
Although NONMEM
®
 is the oldest and most widely used population pharmacokinetics 
software, several other software packages are now becoming available such as the 
Phoenix
®
 NLME
™
. One desirable feature in this new software package is a graphical user 
interface and menu-driven covariate selection options. Therefore, we compared these two 
software packages in terms of covariates selected and predictive performance using both 
clinical and simulated data. For the tacrolimus data, NONMEM
®
 predictions had lower 
bias and imprecision as compared to Phoenix
®
 NLME
™
. For the clinical data, 
NONMEM
®
 predictions had higher bias but were more precise than the Phoenix
®
 
NLME
™ 
predictions.  
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1.1  Kidney transplantation 
Kidney transplantation is recommended for patients with Stage 4 or 5 end stage chronic 
renal disease (ESRD) healthy enough to withstand transplant or without significant 
comorbidities. According to the Scientific Registry of Transplant Recipients (SRTR) 
Annual Data Report in 2010, 16,830 patients underwent kidney transplantation in 2009. 
Transplantation is associated with increased survival and improved quality of life for 
patients with ESRD [1, 2]. The five year survival rate for a recipient with a primary 
kidney transplant in U.S. is approximately 72% based on the reports from the Organ 
Procurement and Transplantation Network (OPTN).   
A transplantation procedure involves the surgical placement of a kidney in the extra 
peritoneal space of a recipient [2]. The transplanted kidney can be donated by either a 
living or a deceased donor, the former being preferred. The five year allograft survival 
rate from a living donor is 80% whereas from a deceased donor the allograft survival is 
67% [2]. Human leukocyte antigen (HLA) matching is done prior to selection of a 
specific donor kidney for a particular recipient since HLA markers play a vital role in 
humoral and cellular mediated immune responses [3].  
1.2  Immunosuppression 
An immunosuppressive regimen is initiated post-transplant to prevent the patient’s own 
cells from rejecting the kidney graft. Induction immunosuppression is started 
immediately post-transplant using monoclonal or polyclonal antibodies or interleukin-2 
(IL-2) receptor antagonists such as basiliximab. These are usually given for 2-3 doses 
within the first month post-transplant but are not continued long term [4]. Additionally, a 
maintenance immunosuppressive regimen is initiated with calcineurin inhibitors (CNIs, 
such as tacrolimus or cyclosporine), antiproliferative agents (such as azathioprine, 
mycophenolate) and steroids (such as prednisone) [5].    
According to the 2010 OPTN and SRTR Annual Data Report, approximately 80% of the 
initial immunosuppressive regimens in adult kidney transplant recipients in 2009 
consisted of a combination of tacrolimus and mycophenolate. The same source reported 
3 
 
that approximately 75% of the immunosuppressive regimens at one year post-transplant 
in 2008 were comprised of a combination of tacrolimus and mychophenolate. Several 
studies have also demonstrated the superiority of tacrolimus over cyclosporine in 
improving graft survival and decreasing the incidence of acute rejection [6, 7]. This 
highlights the importance of tacrolimus in immunosuppressive regimens after kidney 
transplantation. Because of its importance, it is the topic of this thesis.  
The use of steroids for immunosuppression has been a subject of controversy.  Long term 
steroid use is associated with numerous adverse effects such as hypertension, 
hyperlipidemia, osteoporosis, cataracts, osteonecrosis and infections.  Several regimens 
that avoid or minimize the use of steroids have been proposed such as low-dose steroids, 
steroids on alternate days, tapering of steroids (between 3-6 months or later than 6 
months) and steroid sparing regimens (no steroid use or steroids withdrawn within the 
first 7 days post-transplant) [8, 9] . Research in the past 10 years has focused on 
eliminating or using short courses of steroids in immunosuppressive regimens. However, 
this requires optimal use of other agents such as calcineurin inhibitors.  
1.3 Risks associated with suboptimal immunosuppression 
Optimal immunosuppression is critical for long-term allograft function and survival of 
the transplant recipient [10]. Immunosuppression above the target threshold increases the 
risk for infection and malignancies due to decreased immune responses. It also increases 
the risk for common toxicities associated with high tacrolimus troughs such as 
neurotoxicity, nephrotoxicity, diabetogenesis, gastrointestinal disturbances and 
hypertension [11]. Suboptimal immunosuppression increases the risk of acute rejection of 
the transplanted organ, leading to loss of allograft function [4, 10].   
Rejection of the transplanted kidney is one the main complications arising post-
transplant. Rejection can occur within minutes post-transplant (hyper acute), within days 
to weeks post-transplant (acute) or after months or years post-transplant (chronic) [12]. 
Clinical symptoms of rejection include fever, pain at the transplant site, decreased urine 
output and an increase in serum creatinine. Although these are some of the clinical 
symptoms, rejection is confirmed only with a kidney biopsy [12]. Common factors 
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increasing the risk of rejection include HLA mismatch between donor and recipient, non-
compliance with immunosuppressive therapy, older age of the recipient and African-
American (AA) race and low immunosuppressant levels [13]. 
1.4 Tacrolimus pharmacology 
1.4.1 Mechanism of action 
Tacrolimus (FK 506) is a calcineurin inhibitor and is a very common immunosuppressant 
used in kidney transplantation. It binds to the cytosolic immunophilin, FK506 binding 
protein (FKBP).  The TAC-FKBP complex further binds to the calcium dependent 
phosphatase, calcineurin. Calcineurin is responsible for the activation and translocation of 
nuclear factor of activated T-cells (NF-AT) into the nucleus. This NF-AT is required for 
transcription of IL-2 and other cytokine genes responsible for stimulation of T-cells. The 
binding of FKBP to calcinuerin prevents the activation and translocation of NF-AT and 
thus inhibits the transcription of IL-2 and other cytokines leading to the 
immunosuppressive response [14].  
1.4.2  Clinical pharmacology 
Tacrolimus has poor mean oral bioavailability (25%) and absorption is decreased in the 
presence of food. It is rapidly absorbed with a peak blood concentration occurring in 
about 0.5-1 hours after administration [11]. After absorption, tacrolimus is extensively 
distributed to erthyrocytes (95%) and blood concentrations are on average 15 times 
higher than the corresponding plasma concentrations. It is also 99% plasma protein 
bound (both to albumin and α-1 acid glycoprotein). Tacrolimus also crosses the placenta 
and can be found in breast milk. It undergoes extensive metabolism by cytochrome P450 
3A isoenzymes (primarily 3A5) and < 0.5% of the parent drug is eliminated unchanged 
[11, 15, 16]. 
Whole blood concentrations are measured due to extensive distribution into erythrocytes. 
Trough concentrations are used as a surrogate for systemic exposure for tacrolimus [10]. 
It is routine clinical practice to utilize trough concentrations to guide dose modifications 
for tacrolimus. Higher troughs (10-15 ng/ml) are targeted in the first three months post-
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transplant due to a higher risk of acute rejection in the early period post-transplant. 
Relatively lower troughs (8-12 ng/mL in months 3-12 post-transplant and 5-10 ng/mL 
after a year post-transplant) are targeted in the later period post-transplant when the risk 
of acute rejection is lower. These targets are institution specific and may vary based on 
the recipient’s immunologic risk, choice of induction therapy and other maintenance 
immunosuppressants (such as steroids) [11]. 
Tacrolimus has a narrow therapeutic window with a wide inter-individual variability in 
pharmacokinetics [17]. Initial doses are based on weight and subsequent doses are 
adjusted by the trial and error approach using therapeutic drug monitoring (TDM). 
Despite these rigorous adjustments, a large proportion of trough concentrations are above 
or below the therapeutic range, especially in the immediate period post-transplantation 
thus putting the patient at immunologic or toxicity risk. Hence, understanding the 
pharmacokinetics and variables the variables that affect pharmacokinetics are important.  
  1.5  Clinical factors affecting tacrolimus apparent clearance 
Several clinical factors have been associated with tacrolimus apparent clearance (CL/F). 
These include hematocrit, days post-transplant, previous hepatitis C virus infection, 
diarrhea, race and drug interactions with certain classes of medications such as calcium 
channel blockers (e.g. diltiazem), antifungals (e.g. ketoconazole) and  corticosteroids 
(e.g. prednisone) [4, 18, 19].  
Low packed cell volume is known to be correlated with artifically high tacrolimus 
troughs when microparticle enzyme immunoassay (MEIA) is used for analysis. This 
might result in lowering of immunosuppression as a result of reduced doses due to falsely 
high concentrations [18]. Tacrolimus CL/F decreases with increasing days post-
transplant. This may be related to increased bioavailability or increasing hematocrit due 
to resolution of recipient’s anaemia in the weeks to months post-transplant [19]. Some 
studies have suggested that diarrhea results in increased tacrolimus troughs due to 
modeified gastrointestinal transit time[20]. AAs exhibit higher tacrolimus CL/F than non 
AAs. This is attributed to a difference in allelic distribution of CYP3A5 polymorphism 
between the AA and the non-AA recipients. Certain CYP3A inducers/inhibitors such as 
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antifungals and steroids that are commonly co-administered to transplant recipients are 
known to affect the trough concentrations.  
1.6  Genetic factors affecting tacrolimus apparent clearance 
Tacrolimus is extensively metabolized by the cytochrome P450 3A5 isoenzymes. The 
CYP3A5 6986A>G single nucleotide polymorphism (SNP) is associated with higher 
dose-adjusted tacrolimus exposure. Individuals with one or two CYP3A5*1 alleles are 
CYP3A5 enzyme expressors and have higher 3A5 metabolic capacity and lower 
tacrolimus exposure than individuals who are non-expressors (CYP3A5*3/*3) receiving 
the same dose [21]. In a study involving 178 kidney transplant recipients, 40% of 
CYP3A5 expressors were below their target tacrolimus trough concentrations as 
compared to < 10% of CYP3A5 non-expressors in the first week post-transplant [22]. In 
a study involving 136 kidney transplant recipients, tacrolimus daily dose after day 3 post-
transplant was about 70% higher in CYP3A5 expressors as compared to non-expressors 
[23].  
Tacrolimus is a P-glycoprotein (PGP) substrate. Polymorphisms in PGP, an efflux 
transporter present on the apical membrane of many cells, have been studied for their 
effect towards tacrolimus troughs. It is hypothesized that higher expression of PGP on 
kidney tubules could potentially lead to rejection due to efflux of tacrolimus out of its site 
of action. The investigated polymorphisms include ABCB1 3435C>T, 1236 C>T, and 
2677 G>T/A. However, their effect on tacrolimus exposure is controversial and its role, if 
any, is likely minor [21, 24]. 
Therefore, numerous variables that affect tacrolimus troughs need to be assessed. This 
may be done using various tools like mixed effect models which can lead to clinical 
dosing models for tacrolimus in kidney transplant recipients.   
1.7  Population pharmacokinetics 
 1.7.1  Introduction 
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Population pharmacokinetics (PopPK) is a quantitative assessment of pharmacokinetic 
parameters and variability in drug exposure and response. Traditional pharmacokinetic 
studies use the two-stage approach where pharmacokinetic parameters are obtained first 
from each individual. Mean and variability are calculated in the second stage. PopPK 
allows the estimation of pharmacokinetic information from sparse data arising out of the 
population at which the drug is targeted. It allows for estimation of a population mean 
pharmacokinetic parameters (typical value of clearance in the population) as well as 
interindividual variability (IIV) and residual unexplained variability (RUV) [25, 26]. A 
powerful aspect of PopPK is that various underlying demographic, environmental, 
pathophysiological and drug-related factors in the cohort can be explored in an attempt to 
identify the specific factors involved in variability of drug exposure and response [27].   
PopPK analysis has several advantages over the traditional pharmacokinetic analysis. 
Most traditional pharmacokinetic analyses utilize data from a homogeneous cohort of 
subjects with intensive sampling at the same time points for all individuals. Unlike 
traditional studies, PopPK allows the quantification of pharmacokinetic parameters with 
sparse time point sampling and/or unbalanced designs collected as a part of a routine 
clinical study. It allows us to study special populations, such as elderly or neonates, in 
which the drug is to be administered but only a few blood samples can be obtained due to 
ethical or medical reasons. Due to its ability to analyze sparsely collected data, it is more 
cost effective than a traditional PK study that requires intensive sampling. Another 
advantage is that data from several studies (such as different centers, plasma and whole 
blood, bound and unbound concentrations, etc.) can be pooled together and analyzed 
using the PopPK approach [25].   
1.7.2. Nonlinear mixed effects modeling 
Non-linear mixed effects modeling is commonly utilized for PopPK analysis. It quantifies 
the drug concentration/exposure (PK) in the body which can be further used to explain its 
relationship to effects in the body (PD). The term “mixed effects” is used since both fixed 
and random effects are quantified simultaneously. There are 4 mains components to a 
mixed effects model [28]:  
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1. Structural model, which is the basic PK and/or PD model. This describes the 
overall trend in the data such as one-compartment PK model or an Emax PD model.  
2. Covariate model, which attempts to explain the variability in the overall trend 
based on various demographic, environmental, pathophysiological and drug-related 
factors.  
3. IIV model, which quantifies the between subject variability in the cohort 
4. RUV model, which quantifies the remaining variability as a result of errors in the 
assay, inaccurate dose or sampling time, etc.  
The typical value of a pharmacokinetic parameter for a drug, such as clearance (TVCL) 
or volume (TVV), is the estimate of the average (or typical) value of that particular 
parameter in the population. As an example, TVCL is estimated as: 
TVCL= θ1     (1) 
If clearance is dependent on a covariate such as creatinine clearance (CrCL), we can 
describe that covariate relationship as shown below where θ2 accounts for the effect of 
CrCl on drug clearance: 
TVCL= θ1 + θ2*CrCL     (2) 
However, each individual has some IIV in clearance. Clearances for each individual in 
the study population, CLi, can then be described as: 
CLi = TVCL + ηi     (3) 
, where ηi is the IIV which is normally distributed with a mean of 0 and a variance of ω
2
, 
i.e. ηi ~ N (0, ω
2
). 
Finally, the concentration of the ith individual at the jth time (Cobs, ij) point would differ 
from the prediction (Cpred, ij). This is referred to as residual error and quantified as: 
Cobs,ij = Cpred,ij + εij    (4) 
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The εij is the RUV and is normally distributed with a mean of zero and a variability of σ
2
, 
i.e. εij ~N (0, σ
2
).  
1.8  Population pharmacokinetics software 
1.8.1  NONMEM
®
 
NONMEM
®
 is a nonlinear mixed effects modeling software package that is distributed 
by ICON/ Globomax (Ellicott, MD). It is the oldest and most widely used PopPK 
analysis software program. It was developed by Lewis Sheiner and Stuart Beal in the 
1980s and is written in ANSI Fortran 77. It has several components: 1) NONMEM, 
which the non-linear regression program; 2) NM-TRAN, a preprocessor that allows 
inputs in a user-friendly manner; and 3) PREDPP, which has pre-specified subroutines 
for handling PK data.  NONMEM
®
 has a versatile modeling platform. It allows users to 
implement pre-defined models or construct new models. Several interfaces are available 
that allow easy pre-processing and post-processing of NONMEM
®
 runs. One example is 
PDx-POP that is an interface used to operate NONMEM
®
. It provides a user-friendly 
platform to create control streams and run models, to view results and to generate 
statistical and graphical diagnostics [29]. Xpose is an aid to model building in 
NONMEM
®
 that is based on the R-language script. It acts as an add-on to NONMEM
®
 
by assisting in exploration, visualization, model diagnostics, covariate selection and 
model comparison [30]. It is impractical to test covariates within NONMEM
®
 when the 
number of covariates is large because of the number of possible combinations. Xpose 
allows testing of covariates based on additive modeling for further testing in 
NONMEM
®
.  
Parameters in NONMEM
®
 are estimated by the minimization of the extended least 
squares (ELS) objective function value (OFV). The OFV is proportional to the -2 log 
likelihood of the data [31]. Likelihood estimates the probability of the data given the 
model parameters and a higher likelihood (or lower OFV) is indicative of a better fit of 
the model to the data. Since the observed measurement in most clinical study data is 
assumed to follow a normal distribution, the ELS OFV is given as:  
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Random effects enter the model non-linearly and approximations to the non-linear model 
are conducted using Taylor series expansion methods. Most common methods are first-
order (FO) estimation and first-order conditional estimation (FOCE) methods. FO 
involves first-order linearization around the expected mean of the η and ε, (i.e. 0) and 
although once widely used FOCE and FOCE-I are preferred. FOCE involves first-order 
linearization around the conditional values of the η [31]. FOCE and FOCE-I are more-
time consuming than the FO method but they more accurate as observations per 
individual increases due to increased non-linearity of the system.  
1.8.2  Phoenix
®
 NLME
™
 
Phoenix
®
 (Pharsight Corporation, Cary, NC) is a recently developed software package. 
The package comprises of WinNonlin, NLME (non-linear mixed effects) and in-vitro in-
vivo correlations (IVIVC) toolkit. Phoenix
®
 NLME
™
 is the non-linear mixed effects 
software. It has a graphical as well as a textual interface to implement user defined 
models or use pre-defined models from the model library. The user can choose from an 
array of PopPK algorithms such as FO, FOCE-I, adaptive Gaussian quadrature, 
Lindstrom-Bates FOCE, etc. The software is easier to use since most features are menu-
driven. Several covariate modeling algorithms such as running specific pre-defined 
scenarios, stepwise covariate search and shotgun covariate search come as built-in 
functions in Phoenix
®
 NLME
™
 [32]. A maximum of 32 covariates can be tested in 
Phoenix
®
 NLME
™
 in a given model.  
1.9  Covariate modeling 
Covariate modeling is an integral part of any PopPK study. A covariate is a characteristic 
of a subject in a study that could possibly influence a PK/PD outcome. Covariate 
modeling is critical as it can identify factors that can account for a portion of the 
variability. Identifying the source of variability can improve the predictive performance 
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of the model and can provide important contributions to the understanding of PK/PD in 
the population under study.  
1.9.1  Types of covariates 
Covariates may be continuous such as age, weight, creatinine clearance, etc. or 
categorical such as sex (male/female), race (African American or non-African American), 
and concurrent medication (yes/no).  Covariates can also be either time-independent (e.g. 
sex) or they may change over time (e.g.: CrCL). It is important not only to identify 
significant covariates but also to determine the functional form of the covariate 
relationship. For example, age might be a significant covariate for clearance, but the 
relationship may be characterized by several types of relationships (i.e., linear or non-
linear).  
1.9.2  Approaches to covariate modeling 
Several approaches can be used for covariate model building. These are discussed in 
detail below: 
1. Graphical: This involves the use of scatter plots of the empirical Bayes estimates 
(EBEs)/ post-hoc estimates versus the covariate in order to visualize the strength and 
form of the relationship [33]. Scatter plots can be used to examine a possible relationship 
between covariates, if one exists. The relationship is quantified with the help of 
correlation coefficient (ρ). If a correlation is detected (ρ > 0.7), it may be essential to 
select one covariate from amongst the correlated factors. One major drawbacks of this 
method is that it is a subjective assessment and it is harder to detect a weak relationship 
that might exist. If the post-hoc estimates are poor then important covariates might not be 
picked up [34]. 
2. Generalized additive modeling (GAM): This technique is used to find the most 
appropriate model from a given set of covariates. This option can be implemented using 
Xpose. It also utilizes the EBEs to assess a relationship with a covariate. It involves 
regression of EBEs on the covariates.  
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EBEi = α + f1(X1i) + f2(X2i) + … + fn(Xni),   (6) 
where EBEi is the post-hoc estimate for the i
th
 individual and X1i, X2i,…. ,Xni are the ‘n’ 
covariates in the i
th
 individual. Model comparison is done using the Akaike Information 
Criteria (AIC) where ‘p’ is defined to be the number of parameters in the model: 
AIC = -2loglikelihood + 2p     (7) 
This method helps to identify possible significant covariates for analysis within 
NONMEM
®
 when the initial number of covariates is large. This approach saves time by 
reducing the number of models that need to be tested in NONMEM
®
. Also, unlike 
multiple linear regression, it allows a non-linear/spline relationship between the 
covariates and EBEs [34].  However, the method relies on the post-hoc estimates for 
assessing relationships and does not account for time-varying covariates.   
3. Stepwise selection method: This is a widely employed technique of covariate 
selection and involves two steps: forward selection and backward elimination. In forward 
selection, each covariate is entered into the model and the drop in OFV is noted. Based 
on an a priori set p-value, all significant covariates are retained in the model in forward 
selection. When a full model is obtained based on the forward selection criteria, 
backward elimination is carried out using a more stringent p-value to reduce the Type I 
error rate (false positives) in the model. This is done by removal of each covariate from 
the full model one by one. The increase in OFV is noted when each covariate is dropped 
from the model. The final model is obtained by retaining only the significant covariates 
during backward selection. Although this is a widely used method, it suffers from the 
drawback such as false findings, selection bias and problems in adjustment of p-values 
for multiple comparisons.  
There are several methods to parameterize covariates within the context of population 
modeling. Continuous covariates such as weight can be centered (by subtracting the 
mean/median value from the covariate) or standardized (by dividing by the mean/median 
value of the covariate). This is done because PK parameters such as clearance and 
volume are functions of body size such as weight and can mask the effect of other 
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potentially significant covariates [35].  Furthermore, continuous covariates can be 
converted to categorical covariates to allow easy clinical interpretation or due to the 
inability to find a continuous functional form to explain the exact trend. Covariate 
modeling is a challenging and time-consuming aspect of a PopPK modeling project. It is 
necessary to maintain a balance between clinical relevance and statistical significance. 
There is no common consensus on the exact steps needed to conduct a covariate analysis. 
Determining a model that is most useful and clinically relevant model can be somewhat 
of an art. 
1.10 Aims and scope of dissertation 
Personalized medicine is an emerging field of healthcare that attempts to utilize an 
individual’s characteristics to guide dosing [36]. Characteristics used can be demographic 
factors such as age, weight, race, co-medications, etc. and genotype. An important step 
towards implementing personalized medicine into clinical practice is to understand how 
these characteristics could explain the interindividual variability in drug response. This is 
especially true of drugs such as tacrolimus that have a narrow therapeutic index and show 
a large variability in their pharmacokinetics.  An excellent example is the dosing of 
warfarin based on several clinical and genetic factors [37]. The warfarin algorithm uses 
each individual’s unique set of clinical and genetic information to estimate a dose.  We 
wanted to utilize a similar approach for estimating tacrolimus doses due its narrow 
therapeutic window, acute rejection/toxicity with sub-optimal trough concentrations and 
large interindividual variability in response.  
The primary aim of this dissertation was to formulate a model for tacrolimus that predicts 
trough concentration and facilitates prediction of doses prospectively in adult kidney 
transplant patients. This is especially important in the immediate period post-transplant as 
the risk of acute rejection is high. This objective was achieved by analyzing numerous 
clinical factors and genetic variants in a large cohort of adult kidney transplant recipients 
that could influence tacrolimus troughs by affecting absorption, distribution, metabolism 
and excretion (ADME properties). This forms a basis of Chapter II of this thesis.  
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Once formulated, the model developed in Chapter II was validated. Chapter III focuses 
on this objective. The validation was done using an external dataset of adult transplant 
recipients. Predictive performance was used to assess the ability of the equation to predict 
troughs using prediction errors.  The validation of the equation provides additional 
confidence of using the equation in clinical practice. 
The PopPK analysis in Chapter II was carried out by non-linear mixed effects modeling 
using NONMEM
®
.  Several limitations were identified when the number of covariates to 
be analyzed is large and is addressed in Chapter IV. These include both software 
limitations and practical constraints. As the number of covariates increases, the number 
of models that need to be tested increases non-linearly. With ‘p’ covariates, there are a 
total of 2
p
 possible models. If the number of covariates is large, it is impractical to test all 
subset of models. Built-in functionalities such as generalized additive modeling (GAM) 
in the NONMEM
®
 add-in, Xpose, allow the selection of the “best” model with a given 
set of covariates. However, software limitations start to arise with too many covariates. In 
our dataset, we had 119 single nucleotide polymorphisms (SNPs). GAM procedure in 
Xpose was only able to test combinations of 25 SNPs at one time. Therefore, a method 
was developed that would allow screening of covariates for testing in NONMEM
®
. We 
referred to this method as a novel “winnowing method. The method uses an iterative 
process of random sampling and testing with GAM. This method is able to test for 
covariates in combination and screens covariates based on the number of times they 
appear in the “best model” when sampled. An index is created which ranks covariates 
according to their importance. The method can analyze a large number of covariates. 
Chapter IV deals with this novel winnowing method. 
Finally, NONMEM
®
 is the most commonly used software for PopPK analysis. However, 
new software with diverse features such as menu-driven options and newer 
functionalities are being continuously introduced. One such software is Phoenix
®
 
NLME
™
. We wanted to compare NONMEM
®
 and Phoenix
®
 NLME
™
 in terms of the 
clearance model obtained for tacrolimus and for clinically and/or statistical difference 
between the predictions of doses. This was done in order to ensure that similar results 
will be obtained when using one software package over another. A particular analysis 
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may demand extensive covariate selection which might be easily dealt with in Phoenix
®
 
NLME
™
. Chapter V of the thesis addresses the differences in models between 
NONMEM
®
 and Phoenix
®
 NLME
™
.  
In summary, this thesis will present the development and validation of a model that 
attempts to prospectively predict tacrolimus trough concentrations, especially in the 
immediate period post-transplant, to improve dosing in patients. The long term goal of 
this work is to improve immunosuppressive regimen of tacrolimus for successful kidney 
transplantation. It presents the development and validation of a novel method that can be 
used to screen covariates for testing in NONMEM
®
. Finally, we compare NONMEM
®
 
and Phoenix
®
 NLME
™
 for parameter estimates and final models obtained using both 
software packages.  
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Dosing equation for tacrolimus using genetic variants and clinical factors 
21 
 
2.1  Introduction 
Tacrolimus is the most widely used calcineurin inhibitor in kidney transplantation [1].  It 
has a narrow therapeutic window with wide inter-individual variability in 
pharmacokinetics and clearance (CL) [2, 3].  Higher troughs are associated with 
increased risk of toxicity whereas lower troughs are associated with increased risk of 
rejection [4].  Two recent studies showed that with contemporary immunosuppressive 
regimens (tacrolimus, mycophenolate and steroids ± antibody induction) low tacrolimus 
troughs in the first week post-transplant were associated with a greater risk of acute 
rejection [5, 6].  To better tailor therapy, multiple clinical factors have been explored to 
determine their effects on tacrolimus pharmacokinetics.  It is generally acknowledged 
that drug interactions, hematocrit, corticosteroid therapy, day post-transplant, and race 
affect tacrolimus pharmacokinetics [3, 7-10].  It is also established that the cytochrome 
P4503A5 (CYP3A5)*1 allele is associated with significantly higher tacrolimus CL and 
lower systemic exposure [11-15].  However, because tacrolimus troughs are routinely 
monitored and dose adjusted based on trough measurements the effect of these factors are 
not regarded in a consistent manner by centers and a trial and error approach to dosing is 
still common practice.  These factors have not been used to guide dosing primarily due to 
the lack of robust, clinically feasible dosing models that combine important factors.  
Because of the growing use of steroid sparing or avoidance protocols, the importance of 
early immunosuppression intensity provided by the calcineurin inhibitors and/or other 
immunosuppressive exposure is considered important in minimizing acute rejection [16].  
A recent randomized trial studied CYP3A5 genotype guided tacrolimus dosing in kidney 
transplant recipients [17].  In the genotype guided group, patients with one or more 
CYP3A5*1 alleles received an initial tacrolimus dose of 0.3 mg/kg/day and those without 
a *1 allele received a dose of 0.15 mg/kg/day.  The non-genotype guided group was 
administered 0.2 mg/kg/day.  In the genotype guided group, 43.2% of subjects achieved 
the trough target compared to 29.1% in non-genotype guided group (p=0.03).  Although 
using genotype guided dosing was significantly better, the overall proportion of patients 
achieving the therapeutic range may not be sufficient to justify the cost of incorporating 
genotyping into clinical practice.  It is possible that addition of clinical factors and/or 
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other genotypes to dosing models may further improve the initial dose estimates and the 
number of patients achieving the therapeutic target.  However, defining these factors and 
the development of a robust dosing model for clinical use requires a large study 
population.  Therefore, we studied the effect of clinical and genetic factors on tacrolimus 
apparent clearance (CL/F) in a large kidney transplant population through a multicenter 
study.  Our objective was to define the important clinical and genetic factors pertinent 
towards tacrolimus CL/F and develop a dosing model which would be suitable for the 
clinical setting.   
2.2 Methods 
2.2.1 Patient selection and recruitment 
Subjects for this analysis were obtained from the first 1000 patients with end-stage renal 
dysfunction undergoing kidney or kidney-pancreas transplant enrolled in the 
Deterioration of Kidney Allograft Function (DeKAF) Genomics study.  This is a multi-
center observational trial to define genetic and clinical determinants associated with 
clinical outcomes after kidney transplant.  Details of the trial have been published 
elsewhere and are registered at www.clinicaltrials.gov (NCT00270712).  Patients were 
recruited from 2005-2007. A total of 681 patients, ≥18 years of age, who received 
tacrolimus at any time in the first 6 months post-transplant were selected for this analysis.  
The remaining subjects received cyclosporine and were not studied.  Institutional Review 
Board Human Subjects Committee approval was obtained at each participating center.  
All recipients provided written informed consent.   
Tacrolimus trough concentrations (n=11,823) in 681 patients were obtained during oral 
administration in the first 6 months post-transplant.  All patients were administered 
Prograf either once or twice daily. Troughs were obtained as part of clinical care at the 
treating center.  The initial tacrolimus dosing was based on an individual’s body weight 
and subsequent doses were adjusted based on trough concentrations using institution 
specific targets.  In general, troughs of 8-12 ng/mL were targeted in the first three months 
post-transplant and of 6-10 ng/mL were desired in the months 3-6 post-transplant.  
Trough concentrations, if available, were obtained twice in each of week’s 1-8 post-
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transplant and twice in each of months 3, 4, 5 and 6 post-transplant.  There were a mean 
of 17 trough concentrations per patient (range 1-24).  To ensure that tacrolimus was at or 
near steady state, only trough levels measured after day 2 post-transplant were used in 
this analysis.  Trough concentrations were measured in the clinical laboratories of the 
participating centers.  The majority (97.1%) of tacrolimus whole blood concentrations 
were obtained from centers using liquid chromatography-mass spectroscopy to measure 
trough concentrations.  All troughs were measured in centers using CLIA certified assays 
or CLIA quality assays. 
Recipient and donor demographics and clinical characteristics were obtained from 
medical records and are listed in Table 2.1.  Baseline clinical factors collected were 
recipient age, weight, gender and race (AA or non-AA), donor type (living or deceased), 
donor gender, preemptive transplant, number of prior transplants, immunosuppressive 
regimen and enrolling center.  The concomitant use of a CCB and day post-transplant at 
the time of each trough measurement was also obtained.   
2.2.2 Genotyping and selection of variants for analysis 
Recipient pre-transplant DNA was obtained from the lymphocytes isolated from 
peripheral blood.  DNA was genotyped for 2,724 variants primarily using a customized 
Affymetrix GeneChip (Affymetrix, Santa Clara, CA) [18, 19].  Additional variants were 
genotyped using the SNPlex (Applied Biosystems, Foster City, CA) and Sequenom 
(Sequenom, San Diego, CA) systems.  In a prior analysis, these variants were evaluated 
for their association with dose-normalized tacrolimus concentrations using standard 
regression analysis [20].  Since it was not feasible to evaluate 2,724 variants and their 
combinations in a population pharmacokinetic approach to estimate CL/F, the SNPs with 
a p-value <0.01 from the AA and non-AA populations from the regression analysis, were 
selected for this analysis.  The variants evaluated towards tacrolimus were rs776746, 
rs12114000, rs3734354, rs4926, rs3135506 and rs2608555.  The variants and their allele 
frequencies are given in Table 2.2.   
2.2.3 Population modeling of troughs 
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The data were analyzed by a non-linear mixed-effects approach using the NONMEM
®
 
software (Version 7.1, NONMEM
®
 Project Group, GloboMax LLC, MD) with a Visual 
Fortran compiler (Professional Edition for Windows 11.1, Intel®) and PdxPop (Version 
4.0, ICON Development Solutions).  R 2.4.1 was used for the generation of diagnostic 
plots.  Given the long half-life of tacrolimus (12 hrs) [21, 22] relative to the dosing 
intervals, and the absence of pharmacokinetic sampling at times other than the troughs, 
the concentrations were analyzed according to a steady-state infusion model.  It was 
assumed that the trough concentrations (Cmin) were well approximated by the average 
steady-state plasma concentration (Css, av) of tacrolimus due to its long elimination half-
life and were related to the tacrolimus dose through (CL/F)*: 
Cobs = Dosing Rate/(CL/F)*,     (1) 
where Cobs is the observed tacrolimus trough concentration and dosing rate is the total 
daily dose of tacrolimus (in mg) divided by 24 hrs.  The (CL/F)* is a regression 
parameter that predicts the trough concentrations.  It approximates CL/F when Cmin  ≈  
Css, av , as in the case of drugs that have a long half-life such as tacrolimus.  Using (CL/F)* 
as an approximation to CL/F has the advantage of giving the regression parameter 
clinically relevant meaning in terms of magnitude, units and interpretation.  However, we 
caution the reader that the apparent clearance we describe in the manuscript is only an 
approximation of the actual apparent tacrolimus clearance.  
 The first order conditional approximation estimation with interaction (FOCE-I) was 
utilized.  The pharmacokinetic parameter obtained was the CL/F for tacrolimus.  The 
inter-individual variability (IIV) in CL/F was modeled using an exponential error model 
as shown in the following equation:    
CL/F = TVCL*e
η(1)
,       (2) 
where TVCL represents the typical value of CL/F in the population and η(1) represents 
the IIV in tacrolimus CL/F, η~N (0, ω2).  An additive error model was utilized to 
characterize the residual unexplained variability (RUV) as shown in the following 
equation:
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Cij  = Cpred,ij + εij,       (3) 
where Cij is the j
th
 observed concentration in the i
th
 individual, Cpred,ij is the j
th
 predicted 
concentration in the i
th
 individual and εij is the RUV in tacrolimus CL/F, ε~N (0, σ
2
).  
The clinical factors and the 6 variants described in Table 2.1 and 2.2 were tested for their 
influence on tacrolimus CL/F in the model building phase.  Forward inclusion and 
backward elimination were used to analyze the covariates.  A decrease in objective 
function value (OFV, a goodness-of-fit statistic) of 6.63 or more (p<0.01) was considered 
significant (χ2: 1 degree of freedom, df) in the forward inclusion step.  Backward 
elimination was performed using a more stringent increase in OFV of 10.83 or more 
(p<0.001, 1 df).  Clinical factors that were tested included categorical covariates (day 
post-transplant of trough, recipient gender, race, donor type, donor gender, preemptive 
transplant, number of prior transplants and enrolling center) and continuous covariates 
(age and weight).  Race (Caucasian, AA, Asian, Native American/Aleut/Inuit and 
Hawaiian/Pacific Islander) was categorized as AA or non-AA.  Centers were designated 
as using steroid sparing immunosuppressive regimen if they administered steroids for ≤ 7 
days post-transplant.  Age was tested by standardizing it by the median age (50 years) in 
the population.  Days post-transplant was converted to an ordered categorical covariate 
and classified as: immediate post-transplant (days 3-5), early post-transplant (days 6-10) 
and late post-transplant (days 11-180).  Categorization was done since the model failed to 
converge when days post-transplant was modeled as a continuous function (such as a 
simple continuous function, Bateman function, Emax model, etc).  The concomitant use 
of a CCB at the time of the trough measurement was also analyzed.  Variants were 
initially classified as homozygous for the major allele, heterozygous for the minor allele 
or homozygous for the minor allele.  However, the frequency of homozygous variant 
carriers in 5 of the 6 variants was ≤5%.  Therefore, for these 5 variants, the genotypes 
were categorized as 2 variables (carriers or non-carriers of the minor allele).  The minor 
allele frequency (MAF) of CYP3A5*1 was high, therefore, we were able to categorize 
the genotypes as CYP3A5*3/*3, CYP3A5*1/*3, or CYP3A5*1/*1.   
2.2.4 Model building 
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The covariates were tested in a step-wise manner.  In the first step, the OFV for the base 
model (pharmacokinetic model with no covariates) was observed.  The covariates were 
analyzed next by forward inclusion by the following procedure: a) univariate analysis 
was performed, b) the insignificant covariates were removed from further consideration, 
c) the significant covariates (OFV >6.63 for 1 df) were ranked in terms of their 
significance towards tacrolimus CL/F, as assessed by the magnitude of drop in the OFV, 
d) the covariate with the highest rank (i.e. most significant) , was included into an 
updated model  and e) the remaining significant covariates were tested for significance by 
adding them univariately to the updated model.  Steps b) through e) were repeated until 
all the significant covariates were included into the forward inclusion model and all 
insignificant covariates were discarded.  Backward elimination was then performed by 
removing each group within a covariate at a time (e.g. days 6-10 and 11-180 separately).  
An increase in OFV (>10.83 for 1 df) was used to yield the final model.   
2.2.5 Model evaluation 
For the purpose of model evaluation, a nonparametric bootstrap approach was employed.  
A single bootstrap run generated a new dataset, by random sampling with replacement 
from the original dataset.  Bootstrap runs (n=1,000) were performed and nonparametric 
statistics, median and, 2.5
th
 and 97.5
th
 percentile were obtained from successful bootstrap 
runs (successful was defined as achieving both convergence and covariance step).  A 
close agreement between the non-parametric statistics and the estimates from the original 
dataset (≤10%) were indicative of the stability and performance of the population model. 
2.3 Results 
Tacrolimus troughs (n=11,823) from 681 adult kidney transplant recipients obtained in 
the first 6 months post-transplant were studied.  Patient characteristics, tacrolimus doses 
and troughs are given in Table 2.1.  The mean ± S.D. daily doses over the 6 month period 
for the non African American (non-AA) and African American (AA) were 0.07 ± 0.05 
and 0.09 ± 0.04 mg/kg, respectively.  The mean ± SD troughs for the non-AA and AA 
patients were 8.66 ± 3.37 and 6.82 ± 3.51 ng/mL, respectively.  A majority (59%) of the 
subjects received a living donor transplant and 21% of the population was AA.  In our 
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study, in the first week post-transplant, 75% (n=413) of all transplant recipients, 69% 
(n=307) of non-AA and 96% (n=106) of AA, had a trough level <8 ng/mL.  In the second 
week post-transplant, 55% (n=331) of all transplant recipients, 48% (n=228) of non-AA 
and 82% (n=103) of AA, had a trough <8 ng/mL.  The 6 genetic factors and their allele 
frequencies are shown in Table 2.2.  Factors affecting tacrolimus CL/F in order of their 
importance were day post-transplant, presence of CYP3A5*1 allele (rs776746), 
transplantation at a steroid sparing center, recipient age and calcium channel blocker 
(CCB) use (Table 2.3).  The typical value of CL/F was 38.4 L/hr and decreased by 14% 
(0.86) in days 6-10 post-transplant and by 29% (0.71) in days 11-180 post-transplant, 
relative to the days 3-5 post-transplant.  Patients who carried one or more CYP3A5*1 
alleles had lower troughs than those with the CYP3A5*3 allele.  Troughs and dose 
requirements by genotype are shown in Figure 2.1 (panels A and B).  CL/F was increased 
by 69% (1.69) in subjects with the CYP3A5*1/*3 genotype and by 100% (2.00) in 
subjects with the CYP3A5*1/*1 genotype.  CL/F was reduced by 30% (0.70) in patients 
undergoing transplantation at a center using a steroid sparing immunosuppressive 
regimen and by 6% (0.94) when a CCB was co-administered compared to no CCB.  CL/F 
increased until the median age of 50 years and then decreased thereafter.  Recipient 
weight, gender, race, donor type and gender, preemptive transplant, number of prior 
transplants, and the variants rs12114000, rs3734354, rs4926, rs3135506 and rs2608555 
were not significant.  The following equation describes the final model for estimation of 
tacrolimus CL/F in the first 6 months post-transplant.  
CL/F (L/hr) = 38.4*[(0.86, if days 6-10) or (0.71, if days 11-180)]*[(1.69, if 
CYP3A5*1/*3 genotype) or (2.00, if CYP3A5*1/*1 genotype)]*(0.70, if receiving a 
transplant at a steroid sparing center)*[(Age in yrs/50)
-0.4
]*(0.94, if CCB is present) 
 (4) 
The total daily dose (TDD) requirement is then calculated from the estimated tacrolimus 
CL/F above and the desired goal trough concentration. 
TDD (mg) = [CL/F (L/hr) * tacrolimus trough goal (ng/ml) * 24 hrs] / 1000  
 (5) 
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The base model had an IIV of 52.3%. in CL/F. The final model had an IIV of 40.1% in 
CL/F. Thus, the final model was able to explain 23.2% of the relative IIV in CL/F.  Plots 
of the observed (OBS) concentrations versus the model predicted (PRED) concentrations 
and OBS versus the individual predicted (IPRED) concentrations are shown in Figure 
2.2.  A plot of the weighted residuals (WRES) versus time shows that most of the data 
lies within 3 units from the zero-ordinate (Figure 2.2).  In addition, the mean parameter 
estimates from the study population and the 989 successful bootstrap runs are highly 
comparable thereby confirming the accuracy and precision of the estimates as well as 
stability of the final model (Table 2.3).  The post-hoc estimates of CL/F from the final 
model by the 3 different genotypes are shown in Figure 2.3. 
2.4 Discussion 
We report here the first dosing model for tacrolimus using a combination of genetic and 
clinical factors in adult kidney transplant recipients that was developed from one of the 
largest tacrolimus pharmacogenetics studies (n=681) conducted to date.  We found that 
CL/F was significantly influenced by day post-transplant, CYP3A5 genotype, 
transplantation at a steroid sparing center, recipient age, and the use of a CCB.  The 
population CL/F was 38.4 L/hr and is close to estimates from other pharmacokinetic 
studies (ranging from 21-35 L/hr) [10, 23, 24].  Our estimate of CL/F is slightly larger 
than previously reported studies.  This is expected because, as stated earlier, we model 
(CL/F)*, an approximation to the tacrolimus apparent clearance.  In addition, differences 
in patient populations between the studies cannot be ignored, nor can the influence of 
covariates that have been included in our model.  
In our study, 75% (n=413) and 55% (n=331) of the transplant recipients had tacrolimus 
trough concentrations <8 ng/mL in the first week and second week post-transplant, 
respectively.  These troughs are below the usual trough goal in centers participating in 
this study (8-12 ng/mL in the first 3 months).  These troughs were achieved through the 
use of the typical mg/kg dosing and it is possible that a higher number of patients would 
achieve troughs >8 ng/mL if dose individualization using clinical and genetic factors had 
been used.   
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Days post-transplant was the most significant clinical factor affecting tacrolimus CL/F 
and has been previously shown to be associated with CL/F [9, 10, 25, 26].  Tacrolimus 
CL/F decreased by 14% in days 6-10 post-transplant and by 29% in days 11-180 post 
transplant, relative to the immediate post-transplant period (days 3-5).  This decrease in 
CL/F is consistent with previous findings [10, 26].  A decrease in CL/F may be 
attributable to an increase in tacrolimus bioavailability over time as the patients clinical 
status improves.  CL/F may also decrease due to an increase in hematocrit and albumin 
concentrations with time as kidney function is restored. 
The CYP3A5 genotype was also highly associated with CL/F.  Individuals who carry one 
or more CYP3A5*1 alleles express CYP3A5 enzyme [4, 27].  Tacrolimus is a substrate 
for CYP3A5 and it is well established that individuals carrying one or more *1 alleles 
have a higher tacrolimus CL and lower trough concentrations [11-14, 17].  Several 
previous studies have highlighted the differences in CL/F and dose requirements for the 
CYP3A5*1 carriers compared to individuals with the CYP3A5*3/*3 genotype [24, 28-
32].  In a study involving pediatric kidney transplant recipients, tacrolimus CL/F was 
about 50% higher in children with the CYP3A5*1/*1 or *1/*3 genotype as compared to 
the CYP3A5*3/*3 genotype [8].  A recent pharmacokinetic study found tacrolimus CL/F 
to be about 2-fold higher in CYP3A5 expressors (*1/*1 or *1/*3 genotype) as compared 
to the CYP3A5 non-expressors (*1/*1 genotype) [29].  In an earlier study on the 
pharmacokinetics of  tacrolimus in healthy Japanese subjects, CL/F was about 1.5 times 
higher in the CYP3A5*1 carriers (*1/*1 or *3/*3 genotype) as compared to the 
CYP3A5*3/*3 genotype [27].  Most studies have combined genotype groups (*1/*1 with 
*1/*3) due to sample size limitations [13-15, 33].  Given our large sample size, we were 
able to define the differences in tacrolimus CL/F between three CYP3A5 genotype 
groups.  In our study, subjects with the CYP3A5*1/*3 and *1/*1 genotypes had a CL/F 
that was 70% and 100% higher, respectively, than those with the CYP3A5*3/*3 
genotype.  These data demonstrate for the first time that the three CYP3A5 genotypes 
have distinctive CL/F estimates and dose requirements.  The majority (85%) of our non-
AA population had the CYP3A5*3/*3 genotype, whereas the majority (87%) of the AAs 
had the CYP3A5*1/*1 or the CYP3A5*1/*3 genotype.  Despite this race was 
insignificant in our final dosing model most likely due to collinearity between CYP3A5 
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genotype and race.  Although the CYP3A5 genotype is associated with tacrolimus CL/F, 
it is not associated with acute rejection [24, 29, 34].  The lack of association is not 
surprising given that multiple factors increase the risk of rejection (i.e. donor type, 
recipient age, HLA compatibility, low calcineurin inhibitor levels).  Importantly though, 
data show that patients with the CYP3A5*1/*3 or *1/*1 genotype have earlier acute 
rejection and are slower to achieve target concentrations [14].  
Our analysis found an important center effect.  Centers were categorized by the use of a 
steroid sparing immunosuppressive regimen or not.  A steroid sparing 
immunosuppressive protocol administers corticosteroids for a short period of time 
(typically 7-14 days) in the early post-transplant period whereas non-sparing centers 
maintain steroids throughout the first 6 months or longer [35, 36].  We found that CL/F 
was decreased by 30% in patients transplanted at a steroid sparing center.  We 
hypothesize that the center effect is related to steroid use and that continuous therapy 
leads to an induction of CYP enzymes and higher tacrolimus CL/F.  Various studies have 
demonstrated an induction of CYP3A enzymes by corticosteroid therapy [37-39].  
Although controversial, studies have identified corticosteroid therapy as a significant 
factor towards tacrolimus CL/F [9, 40-42].  Clinical practice varies substantially between 
centers; therefore, the attribution of the effect to steroids cannot be confirmed in our 
study and must be directly tested in future analyses.   
Age and CCB use were also identified as significant covariates towards CL/F.  CL/F 
increased progressively up to age 50 years and then decreased thereafter.  The 
concomitant use of a CCB was associated with a small (6%) decrease in tacrolimus CL/F.  
Multiple CCB were used in our study and we did not collect the specific CCB prescribed.  
The CCB, diltiazem, is a well known potent inhibitor of CYP3A enzyme and decreases 
tacrolimus CL/F [30, 31].  Other CCBs (such as amlodipine) are not potent inhibitors of 
CYP3A [43], therefore, the inhibitory effects of some CCBs may be overestimated 
whereas the effect of diltiazem is likely underestimated.   
Since this study is based on a large population, we expect the estimates from this study to 
be fairly reliable.  However, the data for this analysis came from an observational study 
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where supervision of trough measurements was conducted by the clinical teams.  
Hematocrit and aspartate aminotransferase (AST) have been previously shown to be 
important clinical factors [10] and neither was collected in our study.  Future studies 
should also consider concomitant administration of anti-fungals given the potential for 
drug interactions [44, 45].   
The dosing equation which we developed is simple and uses common clinical factors and 
one genotype.  The availability of this equation now allows for the testing of clinical and 
genetic factor guided versus traditional weight-based initial dosing.  Since the 
achievement of therapeutic levels early post-transplant is of importance, we would expect 
the use of individualized dosing to result in a higher proportion of patients within the 
target range and thereby lower the risk for acute rejection.  This model was developed 
from data in adult individuals within the first 6 months post-transplant; therefore, whether 
it can be extrapolated beyond this time frame is not known.  An advantage to our 
equation is that any tacrolimus trough may be targeted including patients where it is 
desirable to provide a higher level of immunosuppression as well as those who may be 
candidates for calcineurin sparing.  
An example of how this model is applied clinically is as follows. Suppose we wish to 
determine prospectively the oral tacrolimus dose in a 50 year old, 85 kg kidney transplant 
recipient on day 3 post-transplant with a goal tacrolimus trough of 10 ng/mL and a 
genotype of CYP3A5*1/*1, in a steroid using center, receiving a CCB. 
CL/F (L/hr) = 38.4*(2.00 for CYP3A5*1/*1 genotype)*[(50/50)
-0.4
]*(0.94 for CCB use) 
= 72.2 L/hr           
 (6) 
The total daily dose (TDD) requirement is: 
TDD (mg) = [72.2 L/hr * 10 ng/ml * 24 hrs] / 1000= 17.5 mg   
 (7) 
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 The daily dose is 17.5 mg or 8.5-9 mg twice daily.  Should this patient have received a 
typical weight based dosing (0.1 mg/kg/day) the estimated dose would be 8.5 mg/day or 
4-4.5 mg twice daily which would have likely under-dosed this patient.   
As another example, let us suppose that we wish to determine the oral tacrolimus dose in 
a 50 year old, 85 kg kidney transplant recipient on day 100 post-transplant with a goal 
tacrolimus trough of 8 ng/mL and a genotype of CYP3A5*3/*3, who underwent 
transplantation at a steroid sparing center, and is not receiving a CCB. 
CL/F (L/hr) = 38.4*(0.71 for days 11-180)* (0.70 for transplant at a steroid sparing 
center) *[(50/50)
-0.4
] = 19.1 L/hr        
 (8) 
The total daily dose (TDD) requirement is: 
TDD (mg) = [19.1 L/hr * 8 ng/ml * 24 hrs] / 1000= 3.6 mg    
 (9) 
 The daily dose is 3.6 mg or 1.5-2 mg twice daily.  Should this patient have received our 
typical weight based dosing (0.1 mg/kg/day) the estimated dose would be 8.5 mg/day or 
4-4.5 mg twice daily which would have likely over-dosed this patient.   
This model now requires confirmation in an independent population and prospective 
testing.   
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Table 2.1: Characteristics in all subjects, non-African Americans & African 
American 
Clinical 
Characteristics 
 All subjects 
(Non-AA & AA) 
Non-AA
1
 AA
2
 
No. of subjects  681 540 (79.3%) 141(20.7%) 
Age (yrs) of recipient
3
  50.2 ± 12.2 50.1 ± 12.2 46.9 ± 11.5 
Baseline weight (kgs)
3
  81.3 ± 18.7 81.1 ± 18.8 81.9 ± 17.9 
Gender of recipient 
(Male/Female) 
 
 
429 (63%) /  
252 (37%) 
338 (63%) /  
202 (37%) 
91 (65%) /  
50 (35%) 
No. of transplants  1 
≥ 2 
550 (81%) 
130 (19%) 
417 (77%) 
122 (23%) 
133 (94%) 
8 (6%) 
No. transplanted at a 
steroid sparing center 
 
 
205 (30%) 
 
197 (36.5%) 
 
8 (5.5%) 
 
Living donor  398 (59%)  355 (66%)  43 (31%)  
No. of troughs  11,823 9,523 2,300 
Tacrolimus dose
4
  0.08 ± 0.05 0.07 ± 0.05 0.09 ± 0.04 
Tacrolimus trough
4
  8.31 ± 3.48 8.66 ± 3.37 6.82 ± 3.51 
No. of patients with 
troughs <8 ng/mL 
Week 1 
Week 2 
413 (75%) 
331 (55%) 
307 (69%) 
228 (48%) 
106 (96%) 
103 (82%) 
Calcium channel 
blocker use
5
 
 5082 (43%) 3915 (41%) 1167 (51%) 
CYP3A5 genotype *1/*1 
*1/*3 
*3/*3 
72 (11%) 
129 (19%) 
476 (70%) 
9 (2%) 
70 (13%) 
457 (85%) 
63 (45%) 
59 (42%) 
19 (13%) 
1
 Non African Americans, 
2
 African Americans, 
3
 reported age and baseline weight are 
those measured at the time of transplant and are mean ± S.D., 
4
 doses (mg/kg/day) and 
troughs (ng/mL) are over the 6 month study period and are mean ± S.D., 
5
 calcium 
channel blocker use at the time of trough collection 
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Table 2.2: Analyzed variants and their allele frequencies in all subjects, non-African 
Americans & African American 
1 
allele frequency in the whole population, 
2
 allele frequency in the Non African 
American, 
3
 allele frequency in the African America 
Reference  
Sequence (rs) No. 
Gene 
Name 
Allele Overall  
Allele 
frequency
1
 (%) 
Non-AA  
Allele frequency
2
 
(%) 
AA allele 
frequency
3
 
(%) 
rs776746 CYP3A5 A 20.16 8.21 65.60 
rs12114000 CYP3A4 A 3.82 0.09 18.09 
rs3734354 SIM1 A 11.40 13.45 3.55 
rs4926 SERPING1 A 23.45 26.63 11.35 
rs3135506 APOA5 C 6.12 6.33 5.32 
rs2608555 GAN T 16.45 15.93 18.44 
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Table 2.3: Final parameter estimates and effect of genetic and clinical factors on 
tacrolimus CL/F 
Parameter  Study population
1
 Bootstrap Analysis
2
 
 Estimate 
(%RSE)
3
 
95% C.I.
4
 
 
Median 
 
2.5
th
- 97.5
th
 
percentiles 
Tacrolimus CL/F
5
  38.4 (4.14) 35.3, 41.5 38.3 35.5, 41.7 
Factors affecting CL/F      
6-10 DPT
6
  0.86 (4.13) 0.80, 0.93 0.86 0.80, 0.93 
11-180 DPT
6
  0.71 (4.14) 0.66, 0.77 0.72 0.66, 0.77 
CYP3A5*1/*3  1.70 (3.99) 1.56, 1.82 1.69 1.56, 1.82 
CYP3A5*1/*1  2.00 (5.90) 1.77, 2.23 1.99 1.77, 2.23 
Steroid sparing center  0.70 (3.50) 0.65, 0.75 0.70 0.65, 0.75 
(Age/50)
θ
  -0.40 (13.5) -0.50, -0.30 -0.39 -0.50, -0.29 
CCB use
7
  0.94 (2.43) 0.89, 0.98 0.94 0.90, 0.99 
IIV
8
 for CL/F, %CV  40.1 37.4, 43.6 40.0 37.4, 43.6 
RUV
9
, additive, SD  3.19 3.07, 3.32 3.19 3.08, 3.32 
1
 681 patients analyzed in this study, 
2 
results from 989 bootstrap runs with successful 
convergence and successful covariance step, 
3
 percent relative standard error, 
4
 
confidence interval: estimate ± (1.96*standard error of estimate), 
5
 typical value of CL/F 
in L/hr, 
6 
days post- transplant,
 7
 calcium channel blocker use at the time of trough 
measurement
, 8
 inter-individual variability, 
9
 random unexplained variability 
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Figure 2.1: Tacrolimus doses and troughs by CYP3A5 genotype over the first 6 
months post-transplant.  
A. Total daily doses by CYP3A5 genotype 
 
B. Trough concentrations by CYP3A5 genotype.  
 
Data are mean and bars represent the standard error 
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Figure 2.2: Goodness-of-fit plots for the final tacrolimus modelal 
 
 
IPRED: Individual predicted concentrations (ng/ml), WRES: Weighted residuals 
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Figure 2.3: Post-hoc estimates of tacrolimus CL/F from the final model over the first 
6 months post-transplant by CYP3A5 genotype 
 
39 
 
2.5 References 
1. Bowman LJ, Brennan DC. The role of tacrolimus in renal transplantation. Expert 
Opin Pharmacother. 2008; 9: 635-43. 
2. Wallemacq P, Armstrong VW, Brunet M, Haufroid V, Holt DW, Johnston A, 
Kuypers D, Le Meur Y, Marquet P, Oellerich M, Thervet E, Toenshoff B, Undre N, 
Weber LT, Westley IS, Mourad M. Opportunities to optimize tacrolimus therapy in solid 
organ transplantation: report of the European consensus conference. Ther Drug Monit. 
2009; 31: 139-52. 
3. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of 
tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004; 43: 623-53. 
4. Laskow DA. An open-label, concentration-ranging trial of FK506 in primary 
kidney transplantation: A Report of the United States Multicenter FK506 Kidney 
Transplant Group1. Transplantation. 1996; 62: 900-5. 
5. Borobia AM, Romero I, Jimenez C, Gil F, Ramirez E, De Gracia R, Escuin F, 
Gonzalez E, Sansuan AJ. Trough tacrolimus concentrations in the first week after kidney 
transplantation are related to acute rejection. Ther Drug Monit. 2009; 31: 436-42. 
6. O'Seaghdha CM, McQuillan R, Moran AM, Lavin P, Dorman A, O'Kelly P, 
Mohan DM, Little P, Hickey DP, Conlon PJ. Higher tacrolimus trough levels on days 2-5 
post-renal transplant are associated with reduced rates of acute rejection. Clin Transplant. 
2009; 23: 462-8. 
7. Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, Roberts JP, 
Hebert MF. Tacrolimus oral bioavailability doubles with coadministration of 
ketoconazole. Clinical pharmacology and therapeutics. 1997; 62: 41-9. 
8. Zhao W, Elie V, Roussey G, Brochard K, Niaudet P, Leroy V, Loirat C, Cochat P, 
Cloarec S, Andre JL, Garaix F, Bensman A, Fakhoury M, Jacqz-Aigrain E. Population 
pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney 
transplant recipients. Clinical pharmacology and therapeutics. 2009; 86: 609-18. 
40 
 
9. Antignac M, Barrou B, Farinotti R, Lechat P, Urien S. Population 
pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. Br J Clin 
Pharmacol. 2007; 64: 750-7. 
10. Staatz CE, Willis C, Taylor PJ, Tett SE. Population pharmacokinetics of 
tacrolimus in adult kidney transplant recipients. Clinical pharmacology and therapeutics. 
2002; 72: 660-9. 
11. Quteineh L, Verstuyft C, Furlan V, Durrbach A, Letierce A, Ferlicot S, Taburet 
AM, Charpentier B, Becquemont L. Influence of CYP3A5 genetic polymorphism on 
tacrolimus daily dose requirements and acute rejection in renal graft recipients. Basic 
Clin Pharmacol Toxicol. 2008; 103: 546-52. 
12. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single 
nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of 
calcineurin inhibitors: Part I. Clin Pharmacokinet. 2010; 49: 141-75. 
13. Renders L, Frisman M, Ufer M, Mosyagin I, Haenisch S, Ott U, Caliebe A, 
Dechant M, Braun F, Kunzendorf U, Cascorbi I. CYP3A5 genotype markedly influences 
the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clinical 
pharmacology and therapeutics. 2007; 81: 228-34. 
14. MacPhee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, Goldberg L, 
Holt DW. The influence of pharmacogenetics on the time to achieve target tacrolimus 
concentrations after kidney transplantation. Am J Transplant. 2004; 4: 914-9. 
15. Zhang X, Liu ZH, Zheng JM, Chen ZH, Tang Z, Chen JS, Li LS. Influence of 
CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after 
renal transplantation. Clin Transplant. 2005; 19: 638-43. 
16. Pascual J, Galeano C, Royuela A, Zamora J. A Systematic Review on Steroid 
Withdrawal Between 3 and 6 Months After Kidney Transplantation. Transplantation. 
2010; 90: 343-9. 
17. Thervet E, Loriot MA, Barbier S, Buchler M, Ficheux M, Choukroun G, 
Toupance O, Touchard G, Alberti C, Le Pogamp P, Moulin B, Le Meur Y, Heng AE, 
41 
 
Subra JF, Beaune P, Legendre C. Optimization of initial tacrolimus dose using 
pharmacogenetic testing. Clinical pharmacology and therapeutics. 2010; 87: 721-6. 
18. Van Ness B, Ramos C, Haznadar M, Hoering A, Haessler J, Crowley J, Jacobus 
S, Oken M, Rajkumar V, Greipp P, Barlogie B, Durie B, Katz M, Atluri G, Fang G, 
Gupta R, Steinbach M, Kumar V, Mushlin R, Johnson D, Morgan G. Genomic variation 
in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to 
detect associations with progression-free survival. BMC medicine. 2008; 6: 26. 
19. Hardenbol P, Baner J, Jain M, Nilsson M, Namsaraev EA, Karlin-Neumann GA, 
Fakhrai-Rad H, Ronaghi M, Willis TD, Landegren U, Davis RW. Multiplexed 
genotyping with sequence-tagged molecular inversion probes. Nature biotechnology. 
2003; 21: 673-8. 
20. Jacobson PA, Oetting WS, Brearley A, Leduc R, Guan W, Schladt D, Matas AJ, 
Lamba V, Julian B, Mannon R, Israni I. Novel Polymorphisms Associated with 
Tacrolimus Trough Concentrations: Results from a Multicenter Kidney Transplant 
Consortium. Transplantation, In Press. 2011; 91: 300-8. 
21. Jusko WJ, Piekoszewski W, Klintmalm GB, Shaefer MS, Hebert MF, Piergies 
AA, Lee CC, Schechter P, Mekki QA. Pharmacokinetics of tacrolimus in liver transplant 
patients. Clinical pharmacology and therapeutics. 1995; 57: 281-90. 
22. Wallemacq PE, Furlan V, Moller A, Schafer A, Stadler P, Firdaous I, Taburet 
AM, Reding R, Clement De Clety S, De Ville De Goyet J, Sokal E, Lykavieris L, Van 
Leeuw V, Bernard O, Otte JB, Undre NA. Pharmacokinetics of tacrolimus (FK506) in 
paediatric liver transplant recipients. Eur J Drug Metab Pharmacokinet. 1998; 23: 367-70. 
23. Staatz CE, Willis C, Taylor PJ, Lynch SV, Tett SE. Toward better outcomes with 
tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in 
adult liver transplantation. Liver Transpl. 2003; 9: 130-7. 
24. Tada H, Tsuchiya N, Satoh S, Kagaya H, Li Z, Sato K, Miura M, Suzuki T, Kato 
T, Habuchi T. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the 
pharmacokinetics of tacrolimus in renal transplant recipients. Transplant Proc. 2005; 37: 
1730-2. 
42 
 
25. Pou L, Brunet M, Andres I, Rodamilans M, Lopez R, Corbella J. Influence of 
posttransplant time on dose and concentration of tacrolimus in liver transplant patients. 
Transpl Int. 1998; 11 Suppl 1: S270-1. 
26. Lee JY, Hahn HJ, Son IJ, Suh KS, Yi NJ, Oh JM, Shin WG. Factors affecting the 
apparent clearance of tacrolimus in Korean adult liver transplant recipients. 
Pharmacotherapy. 2006; 26: 1069-77. 
27. Suzuki Y, Homma M, Doki K, Itagaki F, Kohda Y. Impact of CYP3A5 genetic 
polymorphism on pharmacokinetics of tacrolimus in healthy Japanese subjects. Br J Clin 
Pharmacol. 2008; 66: 154-5. 
28. Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, 
Lindemans J, Weimar W, van Gelder T. Genetic polymorphisms of the CYP3A4, 
CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors 
cyclosporine and tacrolimus. Clinical pharmacology and therapeutics. 2003; 74: 245-54. 
29. Benkali K, Rostaing L, Premaud A, Woillard JB, Saint-Marcoux F, Urien S, 
Kamar N, Marquet P, Rousseau A. Population pharmacokinetics and bayesian estimation 
of tacrolimus exposure in renal transplant recipients on a new once-daily formulation. 
Clin Pharmacokinet. 2010; 49: 683-92. 
30. Tsuchiya N, Satoh S, Tada H, Li Z, Ohyama C, Sato K, Suzuki T, Habuchi T, 
Kato T. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the 
pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation. 2004; 78: 
1182-7. 
31. Zhao Y, Song M, Guan D, Bi S, Meng J, Li Q, Wang W. Genetic polymorphisms 
of CYP3A5 genes and concentration of the cyclosporine and tacrolimus. Transplant Proc. 
2005; 37: 178-81. 
32. Wang P, Mao Y, Zhou X, Wong TS, Patel S, Elliott E, Shea E, Wu HA, Gaber 
AO. Using genetic and clinical factors to predict tacrolimus dose in renal transplant 
recipients. Pharmacogenomics. 2010; 11: 1389-402. 
33. Woillard JB, de Winter BC, Kamar N, Marquet P, Rostaing L, Rousseau A. 
Population pharmacokinetic model and Bayesian estimator for two tacrolimus 
43 
 
formulations--twice daily Prograf and once daily Advagraf. Br J Clin Pharmacol. 2011; 
71: 391-402. 
34. Israni A, Leduc R, Holmes J, Jacobson PA, Lamba V, Guan W, Schladt D, Chen 
J, Matas AJ, Oetting WS. Single-nucleotide polymorphisms, acute rejection, and severity 
of tubulitis in kidney transplantation, accounting for center-to-center variation. 
Transplantation. 2010; 90: 1401-8. 
35. Matas AJ. Minimization of steroids in kidney transplantation. Transpl Int. 2009; 
22: 38-48. 
36. Li L, Weintraub L, Concepcion W, Martin JP, Miller K, Salvatierra O, Sarwal 
MM. Potential influence of tacrolimus and steroid avoidance on early graft function in 
pediatric renal transplantation. Pediatr Transplant. 2008; 12: 701-7. 
37. Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. 
Annu Rev Pharmacol Toxicol. 1999; 39: 1-17. 
38. El-Sankary W, Plant NJ, Gibson GG, Moore DJ. Regulation of the CYP3A4 gene 
by hydrocortisone and xenobiotics: role of the glucocorticoid and pregnane X receptors. 
Drug Metab Dispos. 2000; 28: 493-6. 
39. McCune JS, Hawke RL, LeCluyse EL, Gillenwater HH, Hamilton G, Ritchie J, 
Lindley C. In vivo and in vitro induction of human cytochrome P4503A4 by 
dexamethasone. Clinical pharmacology and therapeutics. 2000; 68: 356-66. 
40. Undre NA, Schafer A. Factors affecting the pharmacokinetics of tacrolimus in the 
first year after renal transplantation. European Tacrolimus Multicentre Renal Study 
Group. Transplant Proc. 1998; 30: 1261-3. 
41. Lam S, Partovi N, Ting LS, Ensom MH. Corticosteroid interactions with 
cyclosporine, tacrolimus, mycophenolate, and sirolimus: fact or fiction? Ann 
Pharmacother. 2008; 42: 1037-47. 
42. Velickovic-Radovanovic R, Catic-Djordjevic A, Milovanovic JR, Djordjevic V, 
Paunovic G, Jankovic SM. Population pharmacokinetics of tacrolimus in kidney 
transplant patients. Int J Clin Pharmacol Ther. 2010; 48: 375-82. 
44 
 
43. Mello de Oliveira L, Bender AL, Traesel MA, Kroth L, Hartmann MJ, Neto SG, 
Saitovitch D, Theisen FV. Therapeutic drug monitoring of tacrolimus in pancreas 
transplantation at São Lucas Hospital. J Bras Patol Med lab. 2007; 43: 339-45. 
44. Capone D, Tarantino G, Gentile A, Sabbatini M, Polichetti G, Santangelo M, 
Nappi R, Ciotola A, D'Alessandro V, Renda A, Basile V, Federico S. Effects of 
voriconazole on tacrolimus metabolism in a kidney transplant recipient. J Clin Pharm 
Ther. 2010; 35: 121-4. 
45. Paterson DL, Singh N. Interactions between Tacrolimus and Antimicrobial 
Agents. Clinical Infectious Diseases. 1997; 25: 1430-40. 
45 
 
 
 
 
Chapter III 
 
Validation of tacrolimus equation to predict troughs using genetic and clinical 
factors 
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3.1 Introduction 
Inter-individual variability in drug exposure and response is a major limitation to drug 
therapy [1].  Although it is generally not clear why patients do not respond to therapy, a 
substantial portion of these individuals may have genetic variability that influences drug 
efficacy, pharmacology and/or systemic exposure [1, 2].  Genetic differences in 
metabolism enzymes and mechanistic pathways are well known to impact 
pharmacokinetics, efficacy and toxicity of warfarin.  To reduce interpatient variability 
and improve efficacy, several dosing equations for warfarin which incorporate genetic 
polymorphisms in cytochrome (CYP) P450 2C9 and vitamin K epoxide reductase 
complex subunit 1 (VKORC1) along with clinical factors (e.g. age, body surface area, 
smoking status, race, age, concomitant medications) have been successfully developed 
[3-7].  Dosing of warfarin by genotype status has been given a level A rating by the 
pharmacogenetics implementation consortium which highlights the potential importance 
of genotype in dose determination [8].  Several studies have shown that genotype-guided 
warfarin dosing resulted in reduced time to stable anticoagulation and faster achievement 
of therapeutic international normalized ratio, and fewer and smaller dose changes [5, 9].  
Tacrolimus is a widely used maintenance immunosuppressant in kidney transplantation 
[10].  It is rapidly absorbed from the gastrointestinal tract and has a poor oral 
bioavailability. It is highly bound to plasma proteins and mainly eliminated through 
metabolism by cytochrome P450 3A5 [11]. Several pharmacokinetic studies have 
estimated the tacrolimus apparent clearance (CL/F) to range from 21-35 L/hr [12-14]. Its 
use is complicated by its narrow therapeutic window and large inter-individual variability 
in pharmacokinetics [15, 16].  Elevated trough concentrations are associated with 
increased risk of toxicity while low troughs are associated with increased risk of rejection 
[17].  In the clinical setting, initial tacrolimus doses are based on body weight and 
subsequent doses are adjusted by therapeutic drug monitoring (TDM) of trough 
concentrations [15].  Despite these efforts, a large number of patients achieve troughs that 
are above or below the targeted therapeutic range, particularly in the early days post-
transplant [18-20].  To address this problem, we developed an equation using 681 kidney 
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transplant recipients, enrolled through a multicenter consortium, using clinical factors and 
genetic variants that individualizes tacrolimus dosing [21].  Our equation estimates an 
apparent CL/F for an individual based on days post-transplant, CYP3A5*1 genotype 
status, transplantation at a steroid sparing transplantation center, age at the time of 
transplant and the use of calcium channel blocker (CCB) (Eq. 1).  Then for any desired 
tacrolimus trough target, the total daily dose (TDD) requirement can be determined using 
the CL/F estimate (Eq. 2).   
CL/F (L/hr) = 38.4*[(0.86, if days 6-10) or (0.71, if days 11-180)]*[(1.69, if 
CYP3A5*1/*3 genotype) or (2.00, if CYP3A5*1/*1 genotype)]*(0.70, if receiving a 
transplant at a steroid sparing center)*[(Age in yrs/50)
-0.4
]*(0.94, if CCB is present) 
  (1) 
TDD (mg) = [CL/F (L/hr) * tacrolimus trough goal (ng/mL) * 24 hrs] / 1000        (2) 
A prerequisite for the clinical use of our clearance equation is to demonstrate its validity 
in predicting troughs.  Therefore, the objective of this study was to evaluate the predictive 
performance of the clearance equation to predict troughs relative to actual observed 
troughs using an independent cohort of kidney transplant recipients.  Validation of this 
equation will provide the additional confidence that our equation can be safely used, may 
reduce the number of out-of-range trough concentrations and ultimately reduce the 
number of troughs concentrations necessary to achieve optimal immune suppression.  
Randomized clinical trials would be a final step to demonstrate the clinical utility of the 
equation.  
3.2 Methods 
3.2.1 Study design  
Patients in which the equation was developed and validated were recruited from the 
multi-center observational trial Deterioration of Kidney Allograft Function (DeKAF) 
Genomics study [21].  Details of the DeKAF Genomics study have been published 
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elsewhere [22-24] and are registered at www.clinicaltrials.gov (NCT00270712).  The 
equation was developed in the 681 subjects who were selected from the first 1000 
subjects enrolled in DeKAF Genomics.  The 795 subjects reported here were selected 
from the next 1000 subjects and were used to validate the equation.  Thus, the validation 
cohort was comprised of a completely separate set of transplant recipient than the 
development cohort.  Approval was obtained from the Institutional Review Board Human 
Subjects Committees at each of the participating centers.  All subjects provided written 
informed consent.  Subject inclusion and exclusion criteria, data collection and analysis 
for the validation cohort were identical to that of the cohort of patients used for 
development of the  equation [21].  Briefly, patients with end-stage renal dysfunction 
undergoing kidney or kidney-pancreas transplant who were ≥18 years of age and received 
tacrolimus (Prograf) at any time in the first 6 months post-transplant were selected for 
this validation analysis.  Clinical data were prospectively collected from the medical 
records.  Tacrolimus trough concentrations were obtained as part of clinical care at the 
treating center after either once or twice daily oral dosing of tacrolimus.  Data were 
collected for the first 6 months post-transplant.  Initial tacrolimus doses were based on 
body weight (mg/kg) as per standard clinical practice at each site.  Subsequent doses 
were adjusted by TDM to achieve institution-specific targets (in general, troughs of 8–12 
ng/mL in the first 3 months post transplant and 6–10 ng/mL in the months 3–6 post 
transplant).  Two trough concentrations were extracted from the medical record in each of 
weeks 1–8 post-transplant and twice in each of months 3, 4, 5 and 6 post-transplant.  
Identical to the dosing equation development, only troughs after day 2 post transplant 
were included in this validation to ensure that tacrolimus was at or near steady state.  
Genotyping for CYP3A5*1 was conducted in all individuals and was previously 
described [21].  
3.2.2 Statistical analysis 
The data were analyzed using the R 12.2.0 statistical package.  For each observed 
tacrolimus trough (Cobs) in the validation cohort, a corresponding CL/F was estimated 
using the previously developed tacrolimus equation (Eq.1).  Our previously developed 
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equation estimated CL/F since tacrolimus was given by the oral route.  From each CL/F 
estimate, a predicted trough (Cpred) was then determined for each Cobs in the validation 
cohort (Eq. 3).    
Cpred (ng/mL) = Dose administered*1000/ (CL/F),     (3) 
where dose administered is the total daily dose of tacrolimus administered in mg divided 
by 24 hrs and CL/F is in L/hr.  
Predictive performance of the equation was evaluated in two ways: 1) absolute 
performance for the initial trough concentrations prior to dose adjustments based on 
TDM information and, 2) relative performance for all trough concentrations over the 
entire 6 months post-transplant compared to a basic apparent clearance model.  The initial 
trough was defined as the first trough measured at steady state in the 1
st
 week post-
transplant.  To ensure that tacrolimus was at or near steady state, only troughs after day 2 
post-transplant were used in this validation.  The mean half-life of tacrolimus is 
approximately 12 hrs and therefore steady state would be achieved in about 60 hrs (2.5 
days) [25].  We did not consider the concomitant use of cytochrome P450 inhibitors or 
inducers (e.g steroids) to make a determination of steady state.  However, we indirectly 
accounted for the steroid effect in the development of the equation using the transplant 
center as a covariate, i.e. having a different CL/F for a recipient receiving transplant at a 
steroid sparing center versus not.  The use of steroids (or not) was a center specific 
practice.  The predictive performance of initial and all troughs was assessed by 
calculation of the bias and precision of the equation using prediction errors.  
First, for the initial troughs (n=412 troughs), the absolute predictive performance was 
evaluated with prediction errors and given as bias and precision of the troughs predicted 
by the equation relative to the Cobs.  Prediction error (PEi) was defined to be the 
difference between Cpred obtained from the equation and the Cobs (which were derived 
from weight based dosing [mg/kg]) (Eq. 4). Bias and precision was calculated as the 
median prediction error (MPE, Eq. 5) and the median absolute prediction error (MAPE, 
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Eq. 6), respectively. A 95% confidence interval for these medians was calculated based 
on binomial probabilities [26].  
PEi= Cpred,i – Cobs,i ,      (4) 
 where Cpred,i is the equation-predicted i
th
 trough, and Cobs,i is the observed i
th
 trough.   
MPE (Bias) = Median (PEi),      (5) 
MAPE (Precision) = Median (|PEi|)    (6) 
Second, the relative predictive performance was evaluated over the entire 6 months 
(n=13,698 troughs).  Relative performance of this model was assessed by comparing it to 
a basic apparent clearance model (derived from the original model before incorporation 
of clinical and genetic variables into the model, Eq. 7) [21].   
Basic tacrolimus apparent clearance, CL/F= 29.7 L/hr  (7) 
The assessment was done using the Wilcoxon signed rank test applied to the paired 
differences (Di) of the median errors (Eq. 8) for relative bias, and to the paired 
differences of the median absolute error (Eq. 9) for relative precision [27].   
Di= PE1i – PE2i     (8) 
Di= |PE1i| – |PE2i|     (9) 
where PE1i was the prediction error from the  equation and PE2i was the prediction error 
from the basic apparent clearance model in the i
th  
trough concentration.  
For assessing relative bias, the null hypothesis (H0) was that the median of the prediction 
errors of the two methods (equation and basic apparent clearance model) are the same.  
For the assessment of precision, the H0 was that the median of the absolute prediction 
errors of the two methods (equation and basic apparent clearance model) are the same.  A 
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p<0.001 was evidence in favor of rejection of H0 and was indicative of a difference in 
bias and precision of the two methods.  
3.3 Results 
The demographics of subjects in the development and validation cohorts are shown in 
Table 3.1.  The observed versus predicted troughs for the initial troughs are shown in 
Figure 3.1.  The absolute predictive performance of the equation for the initial troughs is 
given in Table 3.2.  For the initial troughs, the equation had a MPE (bias) of 0.2 ng/mL 
and a MAPE (precision) of 1.8 ng/mL.  Thus, the initial troughs were slightly over-
predicted by the equation on average by 0.2 ng/mL compared to the actual Cobs.  The 
precision was within ± 18% for a trough of 10 ng/mL and within ± 15% for a trough of 
12 ng/mL.  The relative predictive performance of the equation for all the troughs in the 
first 6 months post-transplant is given in Table 3.3.  The relative performance of the 
equation was assessed relative to a basic apparent clearance model (Eq. 7).  The 
predictive performance of the equation to predict troughs had a MPE (bias) of 0.3 ng/mL 
and a MAPE (precision) of 2.9 ng/mL.  Both MPE (0.5 ng/mL) and MAPE (3.6 ng/mL) 
were higher for the basic apparent clearance model in predicting trough as compared to 
the equation.  From the Wilcoxon signed rank test for relative bias and precision, the p-
value was <0.001 for bias as well as precision.  This supported the rejection of H0 and 
indicated that the median differences from the two methods were different.  Since the 
bias and precision were better for the equation as compared to a basic apparent clearance 
model, the equation was superior to the basic apparent clearance model in predicting the 
trough concentration for all the observed trough concentrations in the first 6 months post-
transplant.   
3.4 Discussion 
Low tacrolimus troughs in the early post-transplant period have been associated with a 
higher rate of acute rejection [20].  Mean trough concentrations in the first week post-
transplant have been shown to be significantly different between rejectors and non-
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rejectors [28, 29].  Assuring that all patients are within the therapeutic target in the early 
post-transplant period would improve therapy [29].  Therefore, we tested how closely our 
equation could predict the actual observed initial tacrolimus trough concentrations.  The 
bias of the equation for the initial troughs was low (0.2 ng/mL).  Moreover, the precision 
for the equation (1.8 ng/mL) was good (i.e. less than ± 20% for a trough of 10 ng/mL).   
We also evaluated the performance of our  equation using all troughs from the first 6 
months post-transplant relative to troughs predicted using an basic apparent clearance 
model which was derived from our previous work in kidney transplant recipients (Eq. 7).  
This is a naïve predictor of CL/F since it does not take into account clinical or genetic 
factors that may affect apparent clearance.  The bias and precision of the equation in 
predicting troughs was significantly better compared to the basic apparent clearance 
model.  This is likely because the equation accounts for important clinical factors such as 
age, co-medications (such as calcium channel blocker) and genetic factors such as the 
CYP3A5*1 status [30].  A naïve CL/F is similar to current clinical practice where all 
subjects receive approximately the same tacrolimus dose (0.08-0.09 mg/kg/day) based on 
body weight.  In our previous analyses, we were unable to show that weight was an 
important determinant of trough. Therefore the use of weight based dosing for tacrolimus 
is probably of limited benefit in tailoring therapy [18, 19, 21].  For all troughs in the first 
6 months post-transplant, the equation had a bias of 0.3 ng/mL and a precision of 2.9 
ng/mL (i.e. less than ± 30 % for a trough of 10 ng/mL).  We believe that the relative 
performance may be more relevant than the absolute performance for all troughs since 
the bias and imprecision is expected to be inflated.  This inflation is likely because the 
reference is a trough measurement that is derived from TDM which incorporates all 
available clinical information.  It is not unexpected that it would have better performance 
than our equation which is based on a few covariates.  The lower predictive performance 
of the equation using all troughs might be attributable to factors such as unknown drug 
interactions, non-compliance, and development of co-morbid conditions which are more 
likely to occur later post-transplant.  In addition, dosing is less closely supervised in the 
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later months post-transplant which may affect the exactness of the trough measurements 
thereby reducing performance. 
Predictive performance analyses suffer from the limitation that reasons for a low 
predictive performance are never clear.  In our case, the lower predictive performance of 
the equation for all troughs may be attributed to the equation itself or inaccuracies in the 
reference (which in this case is the Cobs).  For instance, the Cobs may not have been 
obtained at the ideal trough time point, the patient might be non-compliant, unknown 
drug interactions might be occurring and there might be substantial variability in the 
assay.  When there is inaccuracy in Cobs, the bias and imprecision of the equation is 
overestimated [27].   
Other possible reasons for poor predictive performance is that the equation is 
misspecified or lacks one or more relevant clinical or genetic factors.  The equation does 
not contain adjustments for every possible medication that may interact with tacrolimus.  
However, many of the common potential interacting medications were tested during the 
development phase of the equation (e.g.  ACE inhibitors and antiviral agents) and did not 
influence CL/F [18, 21].  There is a known drug interaction between tacrolimus and 
mycophenolic acid (MPA) which results in alterations in the MPA concentrations (not 
tacrolimus) and therefore concomitant MPA use is not relevant towards the equation [31].  
Additionally, disease states that might affect absorption  and/or gastrointestinal transit 
time (e.g: gastroparesis, malabsorption, diarrhea) was not recorded. We previously tested 
for race in the cohorts and it was not a significant covariate.  However, African American 
race is highly correlated with CYP3A5*1 genotype. Therefore, it was difficult to 
distinguish between effects of race and genotype. Consequently, we are not able to 
quantify these types of effects with the available data. 
In general, the validity of equations can be tested by using either an internal or 
independent external population.  We chose to validate our equation using an external 
cohort of subjects which is considered more rigorous than an internal validation.  
However, it has the caveat that if the predictive performances are not reasonable, it is 
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unfeasible to ascertain whether the unreasonable performance is due to a difference 
between the populations (development and validation cohort) or due to a model 
misspecification [32].  
In conclusion, we conducted a validation of our equation in an independent cohort of 
kidney transplant recipients.  The bias and precision was good for the initial troughs. The 
low bias (over-prediction of 0.2 ng/mL) and high precision (error of less than ± 20% for 
troughs of 10 ng/mL) demonstrated the ability of the equation to predict initial troughs.  
Consequently, we believe that the equation can be safely used for predicting initial 
troughs.  Acute rejection is an early event with two-thirds of events occurring within the 
first 3 months post-transplant and fewer between months 4-6 post-transplant.  It has been 
shown that low exposure to tacrolimus as early as the first week post-transplant is a 
predictor of early acute rejection [29]. Therefore any tools to predict troughs with an 
equation such as the one we developed may get patients to reach the therapeutic dose 
faster and reduce the number of out-of-range toughs and dose changes required.  The 
ability to predict troughs based on an equation instead of the traditional trial and error 
dosing approach may lower overall costs of monitoring.  The cost associated with 
genotyping may be recovered by the reduction in the number of troughs levels obtained 
and staff utilization.  A study to prospectively apply the equation to dose selection is 
needed in the future.  Comparison of the cost-benefit ratio of therapeutic drug monitoring 
with and without this equation was outside the scope of this study.  The future of 
pharmacogenomics is dependent upon developing simple clinical tools that can translate 
genetic association findings into the clinical environment.   Studies such as this 
demonstrate the potential value of genetic based dosing equations.    
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Table 3.1: Characteristics of subjects in the equation development and validation 
cohorts 
Clinical characteristics  Developmen
t cohort 
Validation 
cohort  
No. of subjects  681 795 
Age (yrs) of recipient
1
  50.2 ± 12.2 50.5 ± 13.2 
Baseline weight (kgs) of recipient
 1
  81.3 ± 18.7 83.0 ± 19.3 
Gender of recipient  
(male/female) 
 429(63%)/ 
252 (37%) 
499(63%)/ 
96 (37%) 
Race (Non-African American /African 
American) 
 538(79%)/ 
143(21%) 
652(82%)/ 
143(18%) 
No. transplanted at steroid sparing center  205 (30%) 100 (12.6%) 
Living donor  398 (59%)  465(58.5%)  
No. of troughs  11,823 13,698 
Mean tacrolimus daily dose in mg/kg
2
  0.08 ± 0.05 0.09 ± 0.05 
Mean tacrolimus trough in ng/mL
2
  8.31 ± 3.48 8.53 ± 3.41 
No. of patients with troughs <8 ng/mL  Week 1 
Week 2 
413 (75%) 
331 (55%) 
476 (60%) 
375 (47%) 
Calcium channel blocker use
3
  5082 (43%) 5843 (43%) 
CYP3A5 genotype (rs776746) *1/*1 
*1/*3 
*3/*3 
72 (11%) 
129 (19%) 
476 (70%) 
75 (9.4%) 
147 (18.5%) 
573 (72.1%) 
1
 reported age and baseline weight are those measured at the time of transplant and are 
mean ± S.D., 
2
 doses and troughs are over the 6 month study period and are mean ± S.D., 
3
No. of troughs collected when calcium channel blocker was used 
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Table 3.2: Predictive performance of tacrolimus equation in predicting observed 
initial troughs (n=412 troughs in 412 subjects) 
Absolute predictive performance Equation (95% C.I.) 
MPE (Bias)
1
 0.2 (0, 0.5) 
MAPE (Precision) 
2
 1.8 (1.6, 2.0) 
1 
Mean prediction error indicates
 
the bias of the equation in predicting the initial troughs 
in ng/mL, 
2 
Median absolute prediction errors indicates
 
the precision of the equation in 
predicting the initial troughs in ng/mL 
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Table 3.3: Predictive performance in predicting observed tacrolimus troughs 
(13,698 troughs in 795 subjects) using the tacrolimus equation relative to a basic 
apparent clearance model with no covariates in the first 6 months post-transplant 
Absolute predictive 
performance 
Equation (95% C.I.) Basic clearance model (95% 
C.I.) 
MPE (Bias)
1
 0.3 (0.2, 0.4) 0.5 (0.4, 0.6) 
MAPE (Precision)
2
 2.9 (2.8, 2.10) 3.6 (3.5, 3.7) 
1 
Mean prediction error indicates
 
the bias of the equation in predicting all troughs in 
ng/mL, 
2 
Median absolute prediction errors indicates
 
the precision of the equation in 
predicting all troughs in ng/mL. 
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Figure 3.1: Initial observed troughs versus the initial troughs predicted by the 
clearance equation (n=412) 
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A novel “winnowing method” of covariate selection using tacrolimus 
pharmacogenetics as a motivating example 
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4.1 Introduction 
One of the main components of a population pharmacokinetics (PopPK) analysis is to 
quantify the relationship between covariates and pharmacokinetic parameters [1]. A 
covariate is a characteristic of the patient population such as age, co-medication, etc. that 
accounts for a portion of the variability seen in a drug’s pharmacokinetic-
pharmacodynamic response [1, 2]. Covariate selection is a rigorous process of any 
PopPK analysis. Several methods are available for covariate selection.  
Preliminary analysis involves plotting of the post-hoc/empirical Bayes estimates (EBEs) 
of the individual clearances (CLi) from the base model against covariates to determine the 
strength and shape of any relationship visually [3]. A commonly employed statistical 
method of investigation is the forward selection and backward elimination process using 
a critical cut-off p-value [1, 2, 4]. This method is performed either manually or in an 
automated fashion using Perl Speaks NONMEM (PsN) or other software packages such 
as Phoenix
®
 NLME
™
. Xpose, an add-in for NONMEM
®
, selects the best model from a 
set of covariates based on the Akaike Information Criteria (AIC) using Generalized 
Additive Modeling (GAM) [5]. The covariates selected through GAM can be tested 
further in NONMEM
®
 [6]. 
When the number of covariates is large, an exhaustive analysis of all possible 
combinations can be a time consuming or impractical approach. Software limitations start 
to arise when such a large number of covariates are to be tested. Processing time also 
increases exponentially as the number of covariates increases. As an example, we were 
presented with 119 single nucleotide polymorphisms (SNPs) that could have a potential 
role in tacrolimus apparent clearance (CL/F).  This gives rise to 2
119
 ≈ 1035 combinations. 
When tested using GAM (in Xpose), we were able to assess only 25 categorical SNPs 
(each with 3 levels) at a time. Thus, all SNPs could not be tested together in combination.  
Therefore, the objective of this analysis was to devise and validate a method of covariate 
selection that can be used when there are a large number of covariates. This method 
should be able to select covariates in combination and reduce the processing time needed 
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to select the covariates. We used tacrolimus pharmacogenetics as a motivating example 
to develop this method and validated the method with the help of simulation studies.  
4.2 Methods 
4.2.1 Study Design 
Patient enrollment was done from the multi-center genomics study Deterioration of 
Kidney Allograft Function (DeKAF) observational trial [7]. Details of the DeKAF study 
have been published elsewhere [8-10] and are registered at www.clinicaltrials.gov 
(NCT00270712). Recipient DNA was genotyped for 2,724 SNPs using a customized 
Affymetrix SNP chip. The top 119 SNPs based on a Bonferroni-corrected p-value were 
selected using repeated measures regression analysis in Statistical Analysis Software 
(SAS) and taken forward into the non-linear mixed effects modeling (NONMEM
®
) 
software package. 
4.2.2 Software 
NONMEM
®
 (Version 7.1, NONMEM
®
 Project Group, Globomax LLC) with a Visual 
Fortran Compiler (Windows Professional Edition 11.1) and PdxPop (Version 4.0, ICON 
Development Solutions) as an interface for NONMEM
®
 was used. Additionally, the 
‘gam’ package was installed in the R 12.2.1 statistical package and utilized.  
4.2.3 Population pharmacokinetics modeling 
The structural model was developed from the analysis of 11,823 troughs from 681 kidney 
transplant patients receiving tacrolimus and has been described elsewhere. Briefly, a 
steady state infusion model was utilized to describe the trough concentrations [7].   
4.2.4 Screening of covariates 
A novel “winnowing” scheme was followed to screen the genetic covariates for the 
significant SNPs from amongst the 119 potentially significant SNPs. Winnowing was 
devised to overcome the challenges associated with testing each of the 119 SNPs 
univariately and further in combination with other SNPs.  
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The first step was to obtain the base model (structural PK model with no covariates) 
model and EBEs from NONMEM
®
. Next, a series of GAM runs were devised using the 
‘gam’ package in R.12.2.1. In the first GAM run, the EBEs of CL/F from the base model 
were regressed on a subset of 25 SNPs out of the 119 SNPs. This subset was a group of 
25 randomly selected SNPs from the 119 SNPs (referred to as the group size of the 
random selection process). The most important combination of SNPs in a set of 25 
randomly chosen SNPs was identified based on the AIC. The process was repeated 500 
times (referred to as the number of GAM repetitions) with different subsets of 25 SNPs 
randomly selected each time in order to capture the various possible SNP combinations.  
A SNP index (ranging from 0-1), computed as the number of times a given SNP was 
found in the best-case model, i.e. selected divided by the number of times the SNP was 
chosen at random from the 119 SNPs, i.e. sampled, was created to assign ranks for the 
individual SNPs (Eq. 1). Figure 4.1A shows the histogram of the SNP index after the first 
set of 500 GAM runs.  
sampled is SNP  timesofNumber 
selected is SNP  timesofNumber 
Index SNP    (1) 
After the first winnowing process, SNPs with an index of 0 (never important in a given 
set of SNPs) were eliminated from consideration. SNPs having an index of 1 (i.e. always 
important in a given set of SNPs) were incorporated into the revised model in 
NONMEM
®
. The covariate modeling within NONMEM
®
 was done in a multiplicative 
fashion. The new model with the important SNPs incorporated was re-run in NONMEM
®
 
and the estimates of delta clearance (ΔCL, Eq. 2) were obtained.  
ΔCLi=CLi-TVCL       (2) 
where TVCL is the typical value of the clearance and CLi are the individual clearances.  
The ambiguous SNPs (index 0.1- 0.9) were regressed on the estimates of ΔCLi from the 
revised base model as the dependent variables. This was the second GAM run. Again, a 
group of 25 randomly selected SNPs were regressed on ΔCLi. This process was repeated 
500 times and a second SNP index was generated. 
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The process of running the revised model in NONMEM
®
 based on the SNP index and 
testing the ambiguous SNPs in GAM was repeated until no ambiguous SNPs remained, 
i.e. all SNPs had a SNP index of either 1 or 0 (Figure 4.1B). This was the full covariate 
model from forward selection. Backward elimination was then performed for the full 
model. An increase in objective function (p < 0.05) over the base model was considered 
significant.  
4.2.5 Validation of the method 
PK data were simulated from a one-compartment intravenous (i.v.) bolus model. The 
dataset consisted of 500 individuals with 7 samples per individual drawn at 0.25, 0.5, 1, 
2, 4, 6 and 8 hrs after administration of a 500 mg dose of the drug. The typical value of 
CL was set to 5 L/hr and the typical volume of distribution (Vd) was set to be 14.5 L/hr. 
A proportional error model was assumed for inter-individual variability (IIV) on CL and 
Vd and was set to 30% for both PK parameters. A proportional error model was assumed 
for random unexplained variability (RUV) and set to 10%. Using the R statistical 
package, 100 SNPs with specific allele frequencies were simulated. The effects of 10 
important SNPs on CL were incorporated into the model and the corresponding observed 
concentrations were simulated using NONMEM
®
. The effect sizes of the 10 important 
SNPs and their corresponding allele frequencies were selected from published 
manuscripts and are listed in Table 4.1 [7, 11-16]. The remaining 90 SNPs were 
simulated either at a frequency of 70%, 20% and 10% or 60%, 30% and 10% for 
homozygous dominant, heterozygous recessive and homozygous recessive populations, 
respectively.  
Once the simulated dataset with the specific SNP effects and IIV and RUV had been 
generated, the winnowing scheme was carried out as has been described above. A group 
size of 25 was chosen with 500 GAM repetitions similar to the analysis dataset. The 
objective was to determine if the 10 important SNPs were selected from the 100 SNPs 
available for analysis by this scheme. Type I (false positive) and type II (false negative) 
error rates (Eq. 3 and 4) were also calculated for the approach.  
68 
 
negative True  positive False
positive False
 ySpecificit-1  )(error  I Type   (3) 
positive True  negative False
negative False
 ySensitivit-1  )(error  II Type   (4) 
4.2.6 Sensitivity analysis 
4.2.6.1 Sensitivity to group size and number of GAM repetitions 
The PK dataset used for this sensitivity analysis was the same as used for the validation. 
A sensitivity analysis was performed for the group size and the number of GAM 
repetitions. The group sizes that were tested were 5, 10 and 25 SNPs randomly selected at 
one time. The number of GAM repetitions that were tested included 250, 500 and 1000 
repetitions. Thus a total of 9 combinations were tested. The type I and type II error rates 
were calculated as before (Eq. 3 and 4).  
4.2.6.2 Sensitivity to minor allele frequency and covariate effect size 
A sensitivity analysis was performed for the minor allele frequency and the SNP effect 
size that can be detected using this approach. To decrease the complexity arising out of 
the number of combinations possible, only two allele possibilities were assumed, i.e. 
either carrier of the recessive allele or not. Therefore, the minor allele frequencies that 
were tested included 5%, 10%, 15%, 20% and 30%. The covariate effect sizes that were 
assumed were an increase in CL of 20%, 30%, 40%, 50% and 75% for the carrier of the 
recessive allele. Thus, a total of 25 combinations were possible. The PK dataset was 
similar to that used in the validation analysis. A total of 1000 individuals with 6 samples 
per individual drawn at 0.25, 0.5, 1, 2, 4 and 6 hrs after administration of a 500 mg dose 
of the drug. Using the R statistical package, 100 SNPs with the allele frequencies 
specified above were simulated. The remaining SNPs were simulated with varying minor 
allele frequencies. The effect of the 25 important SNPs on CL was incorporated into the 
model and the corresponding observed concentrations were simulated using NONMEM
®
. 
The winnowing process was performed with a group size of 25 and 500 GAM repetitions 
similar to the tacrolimus analysis.  
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4.3 Results 
4.3.1 Winnowing process for tacrolimus pharmacogenetics 
The winnowing scheme selected 26 SNPs as the full model. The exact process followed 
to obtain these SNPs is depicted in Figure 4.2. It involved a total of 5 updated 
NONMEM
®
 covariate models and 5 runs in GAM to attain the full model. Backward 
elimination was then performed to obtain the 19 SNPs affecting tacrolimus CL/F.  
Amongst the 19 SNPs obtained from winnowing, 6 SNPs were associated with a 2-86% 
increase in CL/F from the base model, 6 SNPs were associated with a 6-38% decrease in 
CL/F from the base model and 7 SNPs were associated with ambiguous CL/F. The details 
of the clinical effects of individual SNPs and alleles are summarized in Table 4.2. Our 
approach selected the CYP3A5*1 SNP which is a well known polymorphism affecting 
tacrolimus CL/F. The role of other SNPs on tacrolimus CL/F is not well established. For 
the ambiguous SNPs, it is possible that the number of individuals in one of the three 
categories of the polymorphism was insufficient to establish a definite effect.  
4.3.2 Winnowing process for validation dataset 
A total of 18 SNPs were picked up the winnowing method for the full model in the 
validation dataset. All true positive SNPs (n=10) and 8 other false positive SNPs were 
selected by the winnowing approach. The type I and type II error rates were 9% and 0%, 
respectively.  
The type I and type II error rates for the sensitivity analysis for the group size and 
number of GAM repetitions is shown in Figure 4.3. In general, for a given number of 
GAM repetitions, the type I error rate decreased with increasing the group size, i.e. fewer 
false positives were obtained with higher group size. For a group size of 25, type I error 
rate was 9% for all the GAM repetitions. For group sizes 5 and 10, the type II error rate 
increased with an increasing number of GAM repetitions, i.e. more false negatives were 
obtained with increasing GAM repetitions. The type II error rate was 0% for all GAM 
repetitions with a group size of 25.  
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For the sensitivity analysis for minor allele frequency and effect size, out of the 25 
important SNPs, 23 SNPs were selected. The 2 SNPs that were not selected had a 
common effect size of 20% and a minor allele frequency of 5% and 10%. The type I and 
type II error rates for this winnowing scheme was 7% and 8% respectively.  
4.4 Discussion 
In this analysis, we developed and validated a novel “winnowing method” for selection of 
covariates when the initial number of covariates is large. We referred to this approach as 
a winnowing method since it is analogous to the winnowing of wheat where the whole 
grain is thrown in the air to separate it from the unwanted part, i.e. chaff. Here, we 
wanted to test the 119 SNPs, remove the unwanted SNPs from consideration and retain 
the important SNPs. These SNPs could be further tested in NONMEM
®
. We used 
tacrolimus pharmacogenetics as a motivating example to develop this method. Using this 
method, followed by backward selection, we were able to select 19 SNPs from the 119 
SNPs. The SNPs selected included the widely established CYP3A5*1, which is well 
known to increase tacrolimus CL/F [17-19].  
We validated this method using a simulation study. The assumptions used for the 
simulation study were reasonable and supported a well-designed pharmacokinetic study 
with precise analytical procedures. The method was able to select all of the 10 important 
SNPs from the 100 SNPs in the validation cohort thus yielding a 0% false negative rate.  
In addition to the true positive SNPs, 8 false SNPs were also selected putting the false 
positive rate of the method to be 10%.  
 We further carried out a sensitivity to explore the combination of iteration group size and 
number of GAM repetitions that would generate the least type I and type II error rates. 
The type I error rate was between 9-12% for all combinations. In general, we found that 
type I error rate was seen to decrease with higher group size for any given number of 
GAM repetitions. The type II error rate was between 0- 10% for all combinations. Type 
II error rate increased with the increase in the number of GAM repetitions for the 5 and 
10 group size but was 0% for all GAM repetitions with the group sizes of 25. For the 25 
group size, with all three GAM repetitions (250, 500 and 1000), the type I and type II 
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error rates were the same. Based on this a group size of 25 with any GAM repetitions 
seems to be the most accurate although 250 GAM repetitions will be the least time 
consuming.  
We also carried out a sensitivity analysis to determine the lowest effect size and/or minor 
allele frequency that a SNP might have before it can be selected by the winnowing 
process. We tested a range of effect sizes (20-75% change in clearance of the recessive 
allele) and minor allele frequencies (5-30%). We saw that a SNP that has a minor allele 
frequency of <10% along with an effect size of ≤ 20% are not detected. Thus, out of the 
25 SNPs that we had, 2 SNPs were not detected.  
Covariates can be tested either within or outside of NONMEM
®
. The main disadvantage 
of testing within NONMEM
®
 is that the process is intensive requiring long run times and 
is sometimes impractical with a large number of covariates. Additionally, when 
covariates are tested using stepwise method using a critical p-value in NONMEM
®
, 
testing is done on several model parameters (e.g. CL, Vd, etc.) and several functional 
forms are explored. This increases the overall probability of false positives due to 
multiple comparisons [20].  
We created a SNP index that ranks SNPs based on the number of times the SNP is 
selected out of the number of times it is randomly sampled. This strategy reduces the type 
I error rate by decreasing the number of times a SNP is tested as compared to when it 
would have been tested if all combinations were accounted for. The remaining SNPs are 
regressed on the ΔCL until all SNPs are either included in the model or are removed from 
consideration since they have a SNP index of 0. Thus, this method utilizes continuous 
feedback from the NONMEM
® 
generated EBEs and is different from simply testing all 
the covariates outside of NONMEM
®
. 
This approach requires the use of the R statistical package. Therefore, the method is free 
to use and easy to implement. The R-script can be added to a NONMEM
®
 add-in such as 
Xpose and can be easily implemented from there.  However, the method has certain 
limitations. It utilizes EBEs and may not be suitable in cases where a substantial amount 
of shrinkage exists. Shrinkage may result in hidden, induced or distorted covariate 
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relationships. Also GAM is unable to handle time varying covariates or inter-occasion 
variability and may not be suitable when such covariates exist.  
We were able to select 26 SNPs by this process out of which 7 were removed by 
backward elimination. In the validation set, we were able to select all the 10 important 
SNPs using the winnowing method. Both the type I and type II error rates were within 
12%. The selection process was sensitive to group size and both type I and type II error 
rates were seen to decrease with increase in the group size for a given number of GAM 
repetitions.  
In conclusion, we developed and validated a novel winnowing method of covariate 
selection using GAM and EBEs from NONMEM. This approach can be utilized when 
there are a large number of covariates (> 25). The method can be made available as an 
add-in to NONMEM
®
. It can be used for initial screening of covariates and the selected 
covariates can be further tested in NONMEM
®
.  
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Table 4.1: Allele frequencies and effect sizes for the 10 significant SNPs used in the 
validation dataset 
SNP Allele frequency
1
 
 (Homoz./Heteroz./Heteroz. Recessive) 
% Change in CL 
SNP 1 60/30/10 100%/ ↓ 40%/ ↓ 65% 
SNP 2 95/5 100%/ ↓ 20 % 
SNP 3 50/45/5 100%/ ↓ 15%/ ↓ 35% 
SNP 4 95/5 100%/ ↓ 40%/  
SNP5 70/20/10 100%/ ↑ 70%/ ↑ 100% 
SNP 6 50/25/25 100%/ ↓ 30%/ ↓ 30% 
SNP 7 85/10/5 100%/ ↓ 50% /↓ 75% 
SNP 8 18/50/32 100%/ ↓ 15%/ ↓ 55% 
SNP 9 25/50/25 100%/  100%/ ↑ 20% 
SNP 10 85/15 100%/ ↑ 30% 
1
 Allele frequency represented as a % for the 10 significant SNPs 
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Table 4.2: SNPs associated with a change in tacrolimus CL/F 
rs number Gene % change in CL/F if 
heteroz. 
% change in 
CL/F if homoz. 
rs776746_A CYP3A5 ↑ 80 ↑ 86 
rs7517376_G FMO1 ↑ 6 ↑ 23 
rs4646312_C COMT ↑ 5 ↑ 17 
rs2295298_A NFATC4 ↑ 4 ↑ 15 
rs848291_T FANCL ↑ 7 ↑ 23 
rs3136228_G MSH6 ↑ 2 ↑ 18 
rs3136516_A F2 ↓ 8 ↓ 17 
rs513349_G BAK1 ↓ 6 ↓ 19 
rs10211_G CYP3A7 ↓ 6 ↓ 18 
rs3734354_A SIM1 ↓ 11 ↓ 38 
rs6330_T NGFB ↓ 8 ↓ 15 
rs12114000_A CYP3A4 ↓ 23 ↓ 26 
rs628816_A DPYD ↓ 13 ↑ 5 
rs3135506_C APOA5 ↓ 16 ↔ 
rs582537_A IL12A ↑ 11 ↑ 5 
rs2332673_C BCL2 ↑ 17 ↓ 13 
rs491347_C LRP5 ↓ 6 ↑ 2 
rs6457815_C PPARD ↓ 4 ↑ 5 
75 
 
Figure 4.1.A. SNP index after first and last set of GAM runs 
 
Figure 4.1.B. SNP index after first set of GAM runs 
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Figure 4.2: Schematic representing the winnowing process for the 119 SNPs for 
tacrolimus 
 
NONMEM
®
       GAM in R 
 
 
Base model                                                                                       CLi ~ 119 SNPs 
 
8 SNPs                                                                                              ΔCLi ~ 74 SNPs  
 
 
14 SNPs                 ΔCLi ~ 49 SNPs  
 
 
20 SNPs                                 ΔCLi ~ 36 SNPs  
 
 
21 SNPs                    ΔCLi ~ 9 SNPs  
 
 
26 SNPs 
EBEs from model with 14 + 6 SNPs with index =1   
7 SNPs with SNP index < 0.1 removed from consideration 
EBEs from new model with 8 + 6 SNPs with index =1 added 
19 SNPs with SNP index < 0.1 removed from consideration 
EBEs from base model  
 25 SNPs randomly selected 
 GAM performed 
 Process repeated 500 times 
EBEs from new model with 8 SNPs with index =1  
37 SNPs with SNP index < 0.1 removed from consideration 
EBEs from model with 20 + 1 SNPs with index =1  
26 SNPs with SNP index < 0.1 removed from consideration 
 Model with 21 + 5 SNPs with index =1  
 4 SNPs with SNP index < 0.1 removed from consideration 
 No ambiguous SNPs remaining 
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 Figure 4.3: Sensitivity analysis of the winnowing process to group size and GAM 
repetitions as assessed by Type I and Type II error rates 
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Chapter V 
 
Comparison of covariate selection between two population pharmacokinetic 
programs, NONMEM
®
 and Phoenix
®
 NLME
™
, using clinical and simulated data 
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5.1  Introduction 
Covariate modeling is an integral part of any population pharmacokinetics (PopPK) 
study. A covariate is any characteristic of a patient population that helps to explain a 
portion of the variability observed in a drug’s pharmacokinetic/pharmacodynamic 
(PK/PD) response [1, 2]. Identifying the strength and mathematical form of a covariate 
relationship is a challenging and time consuming portion of any PopPK analysis [3-5]. 
Once significant covariates are identified as being important to the overall relationship, 
the equation from the final covariate model can be utilized to individualize dosing 
regimens in the clinic [1, 2, 4].  One of the most frequently employed methods for 
covariate modeling is the forward selection and backward elimination approach using a 
goodness-of-fit statistic (objective function value, OFV) [1, 2, 4]. Covariates are entered 
into the model in a stepwise manner based on a critical p-value. Once a full model has 
been obtained by forward selection, the covariates are eliminated sequentially using a 
more stringent critical p-value to avoid Type I error [4].  
Several software packages are employed for PopPK modeling. The oldest and most 
widely used package is the non-linear mixed effects modeling software package 
(NONMEM
®
) [4, 6]. NONMEM
®
 was developed by Lewis Sheiner and Stuart Beal at the 
University of California, San Francisco in the 1980s [6]. Owing to its existence for more 
than 30 years, NONMEM
®
 has more support and discussion forums available than any 
other software package. However, its use requires considerable training and experience 
and is limited to trained users [7]. Other packages are available including Phoenix
®
 
NLME
™
 which was released in 2009 [8]. Phoenix
®
 NLME
™
 has an interface with visual 
work flow and graphic models [7]. The modeling approach in Phoenix
®
 NLME
™
 is 
similar to NONMEM
®
 (non-linear mixed effects modeling). One desirable feature of 
Phoenix
®
 NLME
™
 is the presence of multiple menu-driven covariate selection methods 
(scenario, automated stepwise and shotgun method). When there are a large number of 
covariate relationships to analyze, it is possible to exceed the limitations in both the 
software packages, such as number of fixed effects, or number of columns in data.  A 
menu-driven graphical interface to manage and automate the covariate modeling process, 
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such as that available in Phoenix
®
 NLME
™
, is especially useful since manual testing is 
very time consuming and computer-intensive. Therefore, it may be advantageous to use 
one software package over another for particular analyses. 
Most of the analyses submitted for FDA approval utilize NONMEM
®
. In order to 
facilitate the use of Phoenix
®
 NLME
™ 
for a particular analysis (say involving a large 
number of covariates), comparison of results across software packages is essential in 
order to ensure consistency across platforms [9].  Furthermore, the first-order conditional 
estimation (FOCE) algorithms in NONMEM
®
 and Phoenix
®
 NLME
™
 are slightly 
different which may lead to different results [7]. During covariate selection, slight 
differences in algorithms may result in the selection of a different set of covariates or 
differences in the size of covariate effects.  If these differences are substantial or the drug 
has a narrow therapeutic window, it could lead to variations in clinical interpretation such 
as dose recommendations. Comparison of Phoenix
®
 NLME
™
 with the current gold 
standard (NONMEM
®
) is needed to ensure that results are comparable between software 
packages. 
This analysis utilized data from a retrospective clinical study and a simulation study. The 
purpose was 1) to compare covariate selection by NONMEM
®
 and Phoenix
®
 NLME
™
 
and 2) to identify differences in effect size of the covariates selected, when the same data 
was analyzed by both software packages. The differences were tested for their influence 
on clinical endpoint (such as dose adjustment) for the clinical study and for statistical 
significance (difference in predictive performance) for both the clinical and simulated 
study. Additionally, the automated stepwise selection method and shotgun covariate 
selection in Phoenix
®
 NLME
™
 was explored. 
5.2 Methods 
5.2.1 Population pharmacokinetics 
PopPK analyses consist of 4 main components: 1) determining the basic PK model which 
is also referred to as the structural model, 2) ascertaining the covariate model, which 
identifies the important covariate relationships in the data, 3) determining the inter-
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individual variability (IIV) model and 4) determining the residual unexplained variability 
(RUV) model [8, 10].  
In this analysis, we compared the aspect of covariate model determination using two 
different PopPK modeling software packages, NONMEM
®
 and Phoenix
®
 NLME
™
, using 
tacrolimus PK as an example. The objective for the clinical data was to determine 
covariates that would aid in prospectively predicting the dose for an individual by 
identifying those factors that affect tacrolimus apparent clearance (CL/F). The objective 
for simulated data was to identify factors affecting clearance (CL) for a simulated PK 
dataset. Structural model, error model and initial estimate were set identical in both 
programs. 
5.2.2 Compound 
Tacrolimus is a common maintenance immunosuppressant used in kidney transplantation 
and given for the life of the transplanted kidney. Initial doses are determined by body 
weight (mg/kg dosing) and subsequent doses are adjusted by therapeutic drug monitoring 
(TDM) [11, 12].  
5.2.3 Study design 
5.2.3.1 Clinical data 
This was a seven-center study conducted in the U.S. and Canada. The details of this 
clinical study have been described in previous manuscripts [13, 14]. Briefly, tacrolimus 
troughs (n=11823) from 681 kidney recipients were analyzed. The covariates available 
for analysis were: recipient age, weight, sex and race (African American (AA) or non-
AA), donor type (living or deceased), donor gender, pre-emptive transplant, number of 
prior transplants, enrolling center, concomitant use of a calcium channel blocker (CCB) 
at the time of each trough measurement, use of steroids at the time of each trough 
measurement, days post transplant (DPT) and 6 genetic variants: rs776746, rs12114000, 
rs3734354, rs4926, rs3135506 and rs2608555 [13].  
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5.2.3.2 Simulated data 
PK data were simulated from a one-compartment intravenous (i.v.) bolus model. The 
dataset consisted of 100 individuals with 6 samples per individual drawn at 0.25, 0.5, 1, 
2, 4 and 6 hrs after administration of a 500 mg dose of the drug. The typical value of 
clearance was set to 5 L/hr and the typical volume of distribution was set to be 14.5 L/hr. 
The covariates available for analysis were age, creatinine clearance (CrCL), smoking 
status (yes/no), sex, race (AA or non-AA) and co-medication (yes/no). Covariate effects 
were built into the simulated data. The covariates affecting CL were CrCL, smoking 
status and race. CrCL affected CL according to a power function (Eq. 1).   
      
         (1) 
 
Smoking increased CL by 50% and AA race decreased CL by 30%. A proportional error 
model was assumed for IIV on clearance and volume and it was set to 30%. A 
proportional error model was assumed for RUV and set to 10%. 
5.2.4 Software 
NONMEM
®
 (Version 7.1, NONMEM
®
 Project Group, Globomax LLC) with a Visual 
Fortran Compiler (Windows Professional Edition 11.1) and PdxPop (Version 4.0, ICON 
Development Solutions) as an interface for NONMEM
®
 were used.  Phoenix
®
 NLME
™
 
(Version 1.2, Pharsight Corporation, Cary NC) was used for the comparator analyses.  
5.2.5 Covariate model building 
Covariates were modeled in a multiplicative fashion. Covariate selection in NONMEM
®
 
was performed using the traditional forward selection (p<0.01) and backward elimination 
(p<0.001) approach. The first order conditional estimation with interaction (FOCE-I) was 
utilized. Details of the model obtained by NONMEM
®
 have been extensively reported in 
a prior publication [13]. Selection in Phoenix
®
 NLME
™
 was done using the manual 
7.0
110
CrCL
  CL
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stepwise selection: the forward selection (p<0.01) and backward elimination (p<0.001) 
approach similar to NONMEM
®
. The first order conditional estimation extended least 
squares (FOCE-ELS) algorithm, considered to be the counterpart of FOCE-I in 
NONMEM
®
, was used for Phoenix
®
 NLME
™
. The same approach, i.e. forward selection 
(p<0.05) and backward elimination (p<0.01) with the FOCE-I and FOCE-ELS, was used 
for covariate model building for the simulated data.  
Software packages were assessed in terms of the covariates influencing tacrolimus CL/F 
and their effect size.  For the clinical data, comparison of the two programs was done by 
assessing both clinical and statistical differences. Clinical difference was judged by 
determining the difference in tacrolimus daily doses needed to achieve a typical 
tacrolimus trough of 10 ng/mL in the first two weeks post-transplant for 681 recipients, 
using covariate effects from the final models. The equations from the final CL/F model 
were used to determine a total daily dose (TDD) according to a steady state infusion 
model (Eq.2). The details of this method have been described elsewhere [14].  
TDD (mg) = [CL/F (L/hr) * tacrolimus trough goal (ng/mL) * 24 hrs] / 1000 
 (2) 
where TDD is the total daily dose of tacrolimus administered in mg divided by 24 hrs, 
target tacrolimus trough goal is 10 ng/mL and CL/F is in L/hr from the final covariate 
models. The proportion of levels where doses predicted by NONMEM
®
 and Phoenix
®
 
NLME
™
 differed by ≥ 0.5 mg in the first two weeks post-transplant for a typical trough 
of 10 ng/mL was calculated.   
For both clinical and simulated data, statistical difference was assessed using relative 
predictive performance of the covariate model selected by manual stepwise selection in 
Phoenix
®
 NLME
™
 compared to NONMEM
®
 with the use of prediction errors. Prediction 
error (PEi) was defined to be the residual (Cobs, i- Cpred, i) at each of the ‘n’ trough 
concentrations. Bias and precision of the two methods were calculated as the mean 
prediction error and the root mean squared prediction error, respectively (Eq. 3 & 4).  
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A 95% confidence interval based on standard errors (Eq. 5 & 6) was calculated for 
difference between the bias (ΔME) of Phoenix® NLME™ and NONMEM®. ME1 was 
defined to be the bias from NONMEM
®
 and ME2 was defined to be the bias from 
selection in Phoenix
®
 NLME
™
.  
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Similarly, a 95% confidence interval based on standard errors (Eq. 7 & 8) for the 
difference between the precision (ΔMSE) of Phoenix® NLME™ and NONMEM® was 
calculated. MSE1 was defined to be the squared precision from NONMEM
®
 and ME2 
was defined to be the squared precision from selection in Phoenix
®
 NLME
™
.  
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 If the confidence intervals did not include zero, the bias and/or precision was 
significantly different and the method with the lower bias or imprecision was 
significantly better [15]. 
5.3 Results 
5.3.1 Clinical data 
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The final CL/F model from the manual forward selection and backward elimination 
approach in both software packages selected the same covariates, i.e. days post-
transplant, CYP3A5 genotype, transplant at a steroid sparing center, age at the time of 
transplant and the concomitant use of a calcium channel blocker (CCB) at the time of 
trough (Eq. 8) [13].  
CL/F (L/hr) = TVCL*[(θ1, if days 6-10) or (θ2, if days 11-180)]*[(θ3, if CYP3A5*1/*3 
genotype) or (θ4, if CYP3A5*1/*1 genotype)]*(θ5, if receiving a transplant at a steroid 
sparing center)*[(Age in yrs/50)
-
 
θ
6]*( θ7, if CCB is present)    
  (8) 
where TVCL is the typical value of clearance in the population and θ represents the 
magnitude of the covariate effect sizes. The covariate effect sizes, percent relative 
standard errors (%RSE) and results from 1000 bootstrap runs (median, 2.5
th
 and 97.5
th
 
percentile) are listed in Table 5.1. Parameter estimates were similar for both software 
packages. Comparison of population and individual predictions from the two software 
packages is shown in Figure 5.1.  
In terms of the clinical difference, about 20% of the levels (n=405) differed in predicted 
doses by ≥ 0.5 mg with NONMEM® as compared to Phoenix® NLME™ for a target 
trough of 10 ng/mL in the 1
st
 two weeks post transplant (n=2040).  The absolute 
performance from the two software packages is listed in Table 5.2. In general, the troughs 
by NONMEM
®
 were over-predicted by 0.08 ng/mL while those by Phoenix
®
 NLME
™
 
were over-predicted by 0.09 ng/mL.  For a trough of 10 ng/mL, the precision was within 
± 47.7% and ± 47.8% for NONMEM
®
 and Phoenix
®
 NLME
™
, respectively. In terms of 
the statistical measures of relative performance for comparison between NONMEM
®
 vs. 
Phoenix
® 
NLME
™
, the 95% C.I. for the difference in bias (ΔME) and precision (ΔMSE) 
was (0.007, 0.012) and (-0.34, -0.23), respectively. Since the confidence interval did not 
include zero, it indicated that there was a significant difference in bias and precision 
between predictions from NONMEM
®
 and Phoenix
®
 NLME
™
 (p-value<0.05). The 
method with the lower value of bias and precision was concluded to be significantly 
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better. Therefore, the NONMEM
®
 predictions had significantly lower bias and better 
precision than Phoenix
®
 NLME
™
 predictions. 
When the same clinical data was analyzed using the automated stepwise selection in 
Phoenix
®
 NLME
™
, two additional covariates, i.e. steroid use at the time of trough 
collection and recipient’s weight at the time of transplant were found to be important. 
The covariate effects and median, 2.5
th
 and 97.5
th
 percentiles from 1000 bootstrap runs 
are listed in Table 5.3 for the automated stepwise selection method in Phoenix
® 
NLME
™
. 
In terms of absolute performance, the troughs by Phoenix
®
 NLME
™
 automated selection 
method was over-predicted by 0.04 ng/mL. For a trough of 10 ng/mL, the precision was 
within ± 47.2% for Phoenix
®
 NLME
™
 automated selection.  
5.3.2 Simulated data 
The final CL/F model from the manual forward selection and backward elimination 
approach in both software packages selected the same covariates, i.e. CrCl, smoking 
status and race. The covariate effect sizes, %RSE and results from 1000 bootstrap runs 
(median, 2.5
th
 and 97.5
th
 percentile) are listed in Table 5.4. Parameter estimates were 
similar for both software packages except CrCL. Comparison of population and 
individual predictions from the two software packages for the simulated data is shown in 
Figure 5.2. The estimate for CrCL was predicted more accurately by NONMEM
®
 and 
had a smaller %RSE than Phoenix
®
 NLME
™
. 
The absolute performance is listed in Table 5.5. In terms of absolute performance, the 
concentrations were under-predicted by NONMEM
® 
by 0.24 mg/L and were over-
predicted by Phoenix
®
 NLME
™
 by 0.12 mg/L. The precision was 6.45 and 6.50 mg/L for 
NONMEM
®
 and Phoenix
®
 NLME
™
, respectively. In terms of the statistical measures of 
relative performance for comparison between NONMEM
®
 vs. Phoenix
® 
NLME
™
, the 
95% C.I. for the difference in bias (ΔME) and precision (ΔMSE) was (0.30, 0.41) and (-
1.10, -0.32), respectively. Since the confidence interval did not include zero, it indicated 
that there was a significant difference in bias and precision between predictions from 
NONMEM
®
 and Phoenix
®
 NLME
™
 (p-value<0.05). The method with the lower value of 
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bias and precision was concluded to be significantly better.. Therefore, the NONMEM
®
 
predictions had higher bias but they were more precise than Phoenix
®
 NLME
™
 
predictions.  
The automated stepwise approach in Phoenix
®
 NLME
™ 
yielded the same model as the 
manual method. The shotgun method in Phoenix
®
 NLME
™ 
  tested 64 models (2
6
 models) 
and the best model that could be selected based on ΔOFV was the same as the manual or 
automated stepwise selection scenario.  
5.4 Discussion 
This study utilized clinical and simulated data to compare the covariate model building 
aspect of NONMEM
®
 and Phoenix
®
 NLME
™
. We wanted to identify differences in 
results, if any, when using the same covariate modeling approach and algorithms from 
both software packages. When the manual forward selection backward elimination 
approach with FOCE-I/FOCE-ELS was utilized in both software packages, the 
predictions from NONMEM
®
  had lower bias and were more precise than Phoenix
®
 
NLME
™ 
for the clinical data. When the same approach was followed in both software 
packages for the simulated data, the predictions from NONMEM
®
 had higher bias but 
were more precise than Phoenix
®
 NLME
™
.  
 In order to utilize alternate software packages and features such as the covariate selection 
in Phoenix
®
 NLME
™
 for PopPK analysis, comparisons against the gold standard, (i.e., 
NONMEM
®
) need to be performed. This is important in order to confidently utilize 
functionalities that different packages might offer. Since the FOCE algorithms in 
NONMEM
®
 and Phoenix
®
 NLME
™
 are slight variants of the same algorithm, this study 
compared the covariate model building aspects of the two software packages in selecting 
covariates as well as the covariate effect sizes so as to allow prospective dose 
determination for tacrolimus. We compared the forward selection-backward elimination 
method of covariate selection. This is one of the most commonly used methods for 
covariate selection. Since this had already been implemented in NONMEM
®
 previously 
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[13], we followed the same approach in Phoenix
®
 NLME
™
 to determine if similar results 
are obtained.   
Additionally, Phoenix
®
 NLME
™ 
offers other methods of covariate selection. These 
include 1) scenarios, 2) stepwise selection, and 3) shotgun covariate selection. The 
scenario option allows us to run certain pre-specified scenarios. The list of all possible 
covariate relationships is generated when covariate information is entered into Phoenix
®
 
NLME
™
, and the user can choose a subset of these to consider. The stepwise selection 
mode automates the forward selection and backward elimination procedure to find a 
statistically significantly better model from among the subset of covariate relationships 
that have been chosen for consideration. It generates a text output which describes each 
step of the selection process and lists the best model. The shotgun method tests all 
combinations of scenarios that are possible with a given set of covariates. Since it tests all 
possible combinations, it should only be used when testing a small number of covariates. 
If the number of covariates is large, there could be too many combinations to test in a 
reasonable amount of time. Due to the large number of covariates in this analysis, we also 
performed the automated stepwise selection method in Phoenix
®
 NLME
™
 to obtain the 
covariate model. Additionally, with the simulated data, we performed the shotgun 
covariate search which tests all possible combinations of covariates.  
For the clinical data, Phoenix
®
 NLME
™
 yielded similar covariates as NONMEM
®
 with 
the manual forward selection-backward elimination process. However, when the 
automated covariate selection method in Phoenix
®
 NLME
™
 was employed, two 
additional covariates, steroid use at the time of transplant and weight at the time of 
transplant, were significant. This might be due to differences in the way the forward 
selection-backward elimination was performed manually. The manual method has been 
described previously and was not identical to the automated procedure in Phoenix
®
 
NLME
™
 [13]. Additionally, the final model obtained by the manual selection method was 
based on both clinical judgment and statistical significance. The automated stepwise 
method in Phoenix
®
 NLME
™
 was based solely on statistical significance. For the 
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simulated data, identical results were obtained from both the software packages. The 
stepwise automated selection procedure also gave the same covariate model.  
Clinical difference was ascertained between the two methods by determining the 
proportion of troughs in the 1
st
 two weeks post-transplant in which the dose predictions 
differed by ≥ 0.5 mg between NONMEM® and Phoenix® NLME™ manual stepwise 
selection. Since 0.5 mg is the smallest capsule size for tacrolimus dosing, predictions 
need to differ by 0.5 mg before dose change is feasible [16, 17]. In approximately 20% of 
the troughs, a different dose was predicted with NONMEM
®
 versus Phoenix
®
 NLME
™
 
manual selection. For a patient who is at either end of a therapeutic range, especially for a 
narrow therapeutic range drug such as tacrolimus, a small change of 0.5 mg could result 
in a more favorable or less favorable clinical outcome (no rejection/toxicity). However, 
we want to caution the readers that the clinical impact of this difference in dose from the 
two software packages is drug specific and may not be important in case of a drug that 
has a wide therapeutic window. 
With the simulated data, the estimates and %RSE were similar for the simple selection in 
NONMEM
®
 and Phoenix
®
 NLME
™
. The coefficient of CrCL was slightly different 
between NONMEM
®
 (0.68, 95% C.I.: 0.46, 0.90) and Phoenix
®
 NLME
™
 (0.52, 95% 
C.I.: 0.28, 0.76). The estimation for coefficient of CrCL from NONMEM
®
 was more 
accurate. Other estimates were very similar between both software packages.  
Predictive performance was assessed by bias and precision. In terms of relative 
performance, NONMEM
®
 had better precision than Phoenix
®
 NLME
™
 manual selection 
for both datasets but the bias was higher with NONMEM
®
 for the simulated dataset. The 
reasons for a low predictive performance are never evident.  Inaccurate predictions may 
be attributed to model misspecification or to inaccuracies in the reference concentration, 
i.e. trough concentrations. When trough concentrations are inaccurate, the bias and 
imprecision of the model are inflated [15]. Therefore, we used simulated data for the 
comparator analysis.  
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The use of two different software packages to analyze the same dataset allows direct 
comparison across software packages. Additional factors such as cost of the software 
package and the feasibility of performing a particular analysis in one software package 
versus the other will also contribute in software choice. For example, the menu driven 
automated covariate selection in Phoenix
®
 NLME
™
 can be used when the number of 
covariates is large (say > 15). This would aid in finding the most important covariates 
which can be further tested based on clinical relevance. This process of covariate 
selection requires less time. In the present analysis, the overall time for the automated 
stepwise selection was about 4.5 hours for the clinical data.  
 In conclusion, we compared covariate model building with NONMEM
®
 and Phoenix
®
 
NLME
™
. We observed similar parameter estimates and %RSE for both software 
packages. Automated stepwise selection, available in Phoenix
®
 NLME
™
, yielded two 
additional covariates for the clinical data but could be used as a full model for further 
testing based on clinical relevance. For the clinical data, NONMEM
®
 had a lower bias 
and was more precise than Phoenix
®
 NLME
™
. For the simulated data, Phoenix
®
 NLME
™ 
had a lower bias but NONMEM
® 
was more precise.  
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Table 5.1: Effect sizes of covariates obtained from NONMEM
®
 and Phoenix
®
 
NLME
™ 
for clinical data 
  
NONMEM
®
 Phoenix
®
 NLME
™
 
 Covariate Est. (%RSE) Median (C.I.)* Est.(%RSE) Median (C.I.)* 
TVCL 38.4 (4.1)  38.8 (35.5, 41.7) 37.4 (3.7) 37.7 (34.4, 41.8) 
Factors affecting CL     
DPT (6-10) 0.86 (4.1) 0.86 (0.80, 0.93) 0.90 (3.1) 0.90 (0.81, 0.99) 
DPT (11-180) 0.71 (4.1) 0.72 (0.66, 0.77) 0.73 (2.9) 0.73 (0.66, 0.80) 
CYP3A5*1/*3 1.7 (4.0) 1.69 (1.56, 1.82) 1.69 (4.0) 1.69 (1.56, 1.82) 
CYP3A5*1/*1 2.00 (5.9) 1.99 (1.77, 2.23) 2.03 (5.3) 2.02 (1.80, 2.24) 
Center 0.70 (3.5) 0.70 (0.65, 0.75) 0.71 (3.5) 0.70 (0.65, 0.75) 
(Age/50)
-θ
 0.40 (13.5) 0.39 (0.50, 0.29) 0.39 (12.5) 0.38 (0.50, 0.28) 
CCB 0.94 (2.4) 0.94 (0.90, 0.99) 0.94 (1.3) 0.94 (0.90, 0.98) 
TVCL: Typical value of clearance, * Bootstrap results with 1000 simulations with the 
2.5
th
 and 97.5
th
 percentile, DPT: Days post-transplant, CYP3A5: CYP3A5 genotype, 
Center: Transplant at a steroid sparing center, Age: Age at the time of transplant (in 
years), CCB: Calcium channel blocker use at the time of trough collection, Weight: 
Weight at the time of transplant, Steroid: Steroid use at the time of trough collection
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Table 5.2: Absolute performance for NONMEM
®
 and Phoenix
®
 NLME
™
 manual 
selection for clinical data 
Absolute performance Bias
1 
(95% C.I.) Precision
2 
(95% C.I.) 
NONMEM
®
 -0.08 (-0.16, 0.01) 4.77 (4.68, 4.87) 
Phoenix
®
 NLME
™
 -0.09 (-0.17, -0.001) 4.78 (4.68, 4.88) 
1
Bias (in ng/mL) of the CL/F equation in predicting the troughs , calculated as the mean 
prediction error, 
2 
Precision (in ng/mL) of the equation in predicting the troughs, 
calculated as the root mean squared error 
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Table 5.3: Effect sizes of covariates obtained from Phoenix
®
 NLME
™ 
automated 
stepwise search for clinical data 
Phoenix
®
 NLME
™ 
automated stepwise search 
 Covariate Est.(%RSE) Median (C.I.)* 
TVCL 26.9 (2.82)  26. 9 (25.4, 28.6) 
Factors affecting CL   
DPT (6-10) 1.02 (28) 1.02 (0.99, 1.04) 
DPT (11-180) 1.22 (3.8) 1.22 (1.08, 1.38) 
CYP3A5*1/*3 1.70 (4.0) 1.67 (1.54, 1.80) 
CYP3A5*1/*1 2.00 (5.9) 2.00 (1.79, 2.23) 
Center 0.70 (3.58) 0.70 (0.65, 0.75) 
(Age/50)
-θ
 0.42 (17.6) 0.42 (0.31, 0.52) 
CCB 0.95 (1.27) 0.94 (0.90, 0.99) 
(Weight/70)
θ
 0.31(32.7) 0.30 (0.16, 0.46) 
Steroid 1.14 (2.37) 1.14 (1.05, 1.25) 
TVCL: Typical value of clearance, * Bootstrap results with 1000 simulations with the 
2.5
th
 and 97.5
th
 percentile, DPT: Days post-transplant, CYP3A5: CYP3A5 genotype, 
Center: Transplant at a steroid sparing center, Age: Age at the time of transplant (in 
years), CCB: Calcium channel blocker use at the time of trough collection, Weight: 
Weight at the time of transplant, Steroid: Steroid use at the time of trough collection
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 Table 5.4: Effect sizes of covariates obtained from NONMEM
®
 and Phoenix
®
 
NLME
™
 for simulated data using manual forward selection backward elimination 
approach 
  NONMEM
®
 Phoenix
®
 NLME
™
 
 Covariate Est. (%RSE) Median (C.I.)* Est.(%RSE) Median (C.I.)* 
TVCL 5.1 (4.4)  5.06 (4.56, 5.55) 4.8 (4.5) 5.00 (4.5, 5.5) 
Factors affecting CL 
(CrCL/110)
θ
 0.68 (16.5) 0.69 (0.44, 0.92) 0.52 (23.5) 0.66 (0.45, 0.92) 
SMK 1.6 (7.3) 1.60 (1.39, 1.85) 1.45 (7.3) 1.57 (1.34, 1.84) 
RACE 0.7 (5.8) 0.7  (0.63, 0.79) 0.78  (7.5) 0.71 (0.63, 0.81) 
TVV 14.6 (2.9) 14.6 (13.8, 15.4) 14.5 (3.0) 14.6 (13.7, 15.5) 
TVCL: Typical value of clearance, TVV: Typical value of volume, CrCL: Creatinine 
clearance (mL/min) standardized by the median value, SMK: Fractional change in CL for 
a smoker, RACE: Fractional change in CL for AA, * results from 1000 bootstrap runs 
reported as the median and the 2.5
th
 and 97.5
th
 percentile 
98 
 
Table 5.5: Absolute performance for NONMEM
®
 and Phoenix
®
 NLME
™
 manual 
selection for simulated data 
Absolute performance Bias
1
 (95% C.I.) Precision
2
 (95% C.I.) 
NONMEM
®
 0.24 (-0.28, 0.75) 6.45 (5.73, 7.08) 
Phoenix
®
 NLME
™
 -0.12 (-0.64, 0.40) 6.50 (5.81, 7.12) 
1
Bias (in mg/L) of the CL/F equation in predicting concentrations, calculated as the mean 
prediction error, 
2 
Precision (in mg/L) of the equation in predicting concentrations, 
calculated as the root mean squared error 
 
99 
 
Figure 5.1: Comparison of population and individual predictions from NONMEM
®
 
and Phoenix
®
 NLME
™ 
for the clinical data 
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Figure 5.2: Comparison of population and individual predictions from NONMEM
®
 
and Phoenix
®
 NLME
™
 for the simulated data  
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The overall objective of this work was to formulate and validate a clinical dosing model 
for tacrolimus in kidney transplant recipients by identifying the clinical and genetic 
covariates that might influence tacrolimus CL/F. Tacrolimus is a common maintenance 
immunosuppressant, used widely in transplant recipients.  Patients with suboptimal 
tacrolimus troughs are at a higher risk of rejection of the allograft or at a higher risk of 
toxicity [1]. Therefore, achieving the therapeutic range is important, especially in the 
immediate post-transplant period when the risk of rejection is higher [2].  
The use of tacrolimus is complicated by its narrow therapeutic window (10-15 ng/ml) and 
wide inter-individual variability in pharmacokinetics. Traditionally, the initial dose of 
tacrolimus is based on mg/kg dosing and subsequent doses are adjusted by therapeutic 
drug monitoring.  In spite of such rigorous monitoring, a large proportion of transplant 
recipients are below/above the therapeutic drug levels.  Multiple clinical factors (such as 
days post-transplant, co-medications) and genetic variants (CYP3A5*1) have been 
previously explored to explain inter-individual variability in trough concentrations [3, 4]. 
However, the contribution of these established factors and other possible influential 
factors have not been studied in a combined and consistent manner to generate evidence-
based guidelines that can prospectively predict the dose for a transplant recipient.  
The data for this study came from one one of the largest tacrolimus pharmacogenetics 
studies conducted to date (681 subjects and 11,823 trough concentrations). Recipients 
were genotyped for 2,724 SNPs using a SNP chip. Two types of covariates were 
available for analysis: routine clinical variables (age, weight, co-medication, etc.) and 
119 SNPs. These SNPs were selected from 2,784 SNPs based on a Bonferroni corrected 
p-value by multiple linear regressions of SNPs on dose normalized trough concentrations. 
The top 6 SNPs were selected for the building of the dosing model due to software 
limitations within NONMEM
®
 to analyze the large number of SNPs. The clinical dosing 
model was obtained by non-linear mixed effects modeling of the tacrolimus troughs using 
NONMEM
®
. The troughs were characterized by a steady state infusion model. Clinical 
factors and 6 genetic variants were screened for importance towards tacrolimus clearance 
(CL/F) using the forward selection backward elimination approach. 
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 Our study presents the first dosing model for tacrolimus using a combination of genetic 
variants and clinical factors in adult kidney transplant recipients.  
CL/F (L/hr) = 38.4*[(0.86, if days 6-10) or (0.71, if days 11-180)]*[(1.69, if 
CYP3A5*1/*3 genotype) or (2.00, if CYP3A5*1/*1 genotype)]*(0.70, if receiving a 
transplant at a steroid sparing center)*[(Age in yrs/50)
-0.4
]*(0.94, if calcium channel 
blocker is present)  (1) 
The total daily dose (TDD) requirement is then calculated from the estimated tacrolimus 
CL/F above and the desired goal trough concentration. 
TDD (mg) = [CL/F (L/hr) * tacrolimus trough goal (ng/ml) * 24 hrs] / 1000 
 (2) 
We found that tacrolimus CL/F in kidney transplant recipients was significantly 
influenced by days post-transplant, CYP3A5 genotype, transplantation at a steroid 
sparing center, recipient age, and the use of a calcium channel blocker. CL/F decreased 
with increasing days post-transplant, likely due to an increase in bioavailability with 
improved gastrointestinal motility after transplant. Our large sample size enabled us to 
define the distinct differences in tacrolimus CL/F between three CYP3A5 genotype 
groups (*1/*1, *1/*3 and *3/*3). The presence of *1/*3 genotype increased CL/F by 70% 
and the presence of *1/*1 genotype increased CL/F by 100% as compared to the *3/*3. A 
majority of our non-AA population possessed the CYP3A5*3/*3 genotype and a majority 
of the AA population had the CYP3A5*1/*1 or the CYP3A5*1/*3 genotype.  However, 
race was not found to be a significant covariate, possibly due to a correlation between 
race and CYP3A5 genotype. CL/F was seen to decrease with calcium channel blocker use 
and transplant at steroid sparing center. This is most likely attributed to drug interaction 
as these classes of medications are CYP3A substrates. Our CL/F model is simple and 
utilizes 4 clinical factors and 1 genetic variant. The predicted CL/F can be used to 
prospectively predict dose for a transplant recipient in order to achieve a target trough 
concentration. 
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The next step was to validate the developed equation in an external dataset of transplant 
recipients. We validated the genetic-based tacrolimus equation that predicts troughs in an 
independent cohort of 795 kidney transplant recipients receiving tacrolimus (n= 13698 
troughs). The patient characteristics were similar for the development and validation 
cohort. The performance of the equation to predict initial troughs was assessed by 
calculating bias and precision of the equation.  For all troughs in the first 6 months post-
transplant, a comparison was made between the troughs predicted using the equation 
versus those predicted using a basic apparent clearance model with no covariates.  The 
initial troughs were over-predicted by the equation on an average by 0.2 ng/mL. For a 
typical trough of 10 ng/mL the precision was within ± 20 %. For all troughs over the 6 
months post-transplant, the equation predicted troughs significantly better than the basic 
CL/F model.  Therefore, the tacrolimus equation had good bias and precision in 
predicting initial troughs and performed better than a basic apparent clearance model for 
all troughs.  The equation can be safely used for predicting initial clearance from which 
initial dose can be determined. The validation of the equation provided additional 
confidence to use the equation for predicting troughs. Randomized clinical trials where 
traditional approach (mg/kg dosing followed by TDM) will be compared with our 
equation would be a final step to confirm clinical utility.  
The standard tool for population pharmacokinetic analysis, i.e. NONMEM
®
, is utilized to 
determine the association of the clinical and genetic covariates with tacrolimus troughs. It 
has limitations on the number of covariates that can be modeled at one time. Moreover, 
with even 20 covariates for consideration, the number of possible combinations rise 
exponentially and the modeling becomes very time intensive. Due to software and time 
limitations associated with the large number of SNPs (n=119) and SNP combinations (≈ 
2
119
) in this study, we devised a “winnowing method” that would enable screening of the 
covariates in a much more time-efficient and practical manner. The method uses GAM to 
compare models arising out of randomly selected sub-group of covariates. Next, another 
sub-group of covariates (SNPs) is selected randomly again and GAM is repeated. This 
process of random selection and GAM is repeated several times (say 500) to capture 
various combinations of covariates. The results from these repetitions are summarized by 
creating a SNP index. An index, ranging from 0-1, is the proportion of the number of 
107 
 
times a SNP is selected by GAM (i.e. appears in the final model) to the number of times 
it is randomly selected (i.e. appears in the subgroup). This index defines the relative 
importance of the SNPs. The important SNPs (index =1) are included in an updated 
NONMEM model, unimportant SNPs (index=0) are removed from consideration and 
remaining SNPs (index= 0.1-0.9) are re-tested by regression on the EBE’s from the 
updated NONMEM model. This process is repeated until all SNPs are categorized as 0 or 
1 index SNPs. The full model is obtained by this process and greatly reduces the number 
of SNPs that need to be tested in NONMEM. We further validated this approach using a 
simulated dataset with 10 important SNPs in a group of 100 SNPs. The approach was 
able to identify all the important SNPs. The type I and type II error rates were 9 % and 0 
% respectively.  
The method is run using NONMEM and the R statistical package. It is easy to use and 
reduces the rate of type I error by decreasing the amount of multiple testing [5]. It 
decreases the number of covariates that need to be tested within NONMEM and uses 
feedback from NONMEM (in the form of updated EBEs) to select or reject future 
covariates. Since, the method requires the use of EBEs, it may not however be 
appropriate to use in the presence of high shrinkage. Time varying covariates or inter-
occasion variability can also not be handled with this approach.  
Finally, we compared covariate model building within NONMEM
®
 and Phoenix
®
 
NLME
™ 
using clinical and simulated data. NONMEM
®
, is the oldest and most widely 
used PopPK software [6]. Newer software packages, such as Phoenix
®
 NLME
™
, are 
being developed that provide a graphical user interface and menu-driven options for 
covariate selection [7]. Additionally, several methods of manual and automated covariate 
selection are available within Phoenix
®
 NLME
™
, which makes it much more favorable to 
use in an analysis with a large number of covariates.  
We used the tacrolimus troughs data as well as a simulated dataset to compare both these 
software packages when the same algorithm (FOCE-I in NONMEM
®
/FOCE-ELS in 
Phoenix
®
 NLME
™
) and same covariate selection method (manual forward selection 
backward elimination) was used in both the software packages. Both software packages 
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selected the same covariates with the manual selection method. With the clinical data, 
about 20% of the troughs differed in a dose prediction of ≥ 0.5 mg with NONMEM® 
compared to Phoenix
®
 NLME
™
. With the clinical data, we saw that NONMEM
® 
predictions had better bias and precision than Phoenix
®
 NLME
™
. When we used the 
automated stepwise selection method in Phoenix
®
 NLME
™
, two additional covariates 
were selected as being significant and may be attributed to the difference in which the 
covariate selection was carried out manually versus the automated manner. This method 
was faster and could be used as a full model for further testing in NONMEM
®
. 
NONMEM
®
 predictions had higher bias and lower precision than predictions from 
Phoenix
®
 NLME
™ 
automated stepwise method. With the simulated data, the same 
covariates were selected. Phoenix
®
 NLME
™ 
predictions had better bias but NONMEM
®
 
predictions had better precision. 
In conclusion, we developed and validated a genetics-based model that predicts troughs 
and can be used for prospectively determining tacrolimus doses in kidney transplant 
recipients. We developed and validated a novel “winnowing method” of covariate 
screening for testing within NONMEM
®
. We compared covariate selection using 
NONMEM
®
 and Phoenix
®
 NLME
™ 
based on clinical and statistical differences.  
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Chapter II: NONMEM Code for final model for tacrolimus troughs 
 
;Model Desc: SS ASSUMPTION NO PREDPP 
;Project Name: comb_de_add_final 
;Project ID: Tacrolimus troughs_final 
  
$PROB RUN#064B 
$INPUT C ID PID DAY DV RATE DOSE=DROP MDV TDD=DROP SERN=DROP 
SEX WT WMZ=DROP WMO=DROP WMT=DROP WMS=DROP HT=DROP 
HGT=DROP HTDF=DROP DONR ETHN=DROP RACE CNTR AGE CACB ROID 
PREM DGEN NTRP R354=DROP R926=DROP R746 R000=DROP R506=DROP 
R555=DROP 
$DATA CNITAC2_DE_edited.csv IGNORE=C  
$SUBROUTINES  
$PRED 
 
;Convert days post transplant to a categorical variable 
 
APOD=0 
BPOD=0 
CPOD=0 
 
IF(DAY.LE.5)APOD= DAY 
IF(DAY.GT.5.AND.DAY.LE.10)BPOD=DAY 
IF(DAY.GT.10)CPOD=DAY 
 
TVCL=THETA(1) 
IF(DAY.EQ.BPOD)TVCL=TVCL*THETA(2) 
IF(DAY.EQ.CPOD)TVCL= TVCL*THETA(3) 
IF(R746.EQ.1)TVCL=TVCL*THETA(4) 
IF(R746.EQ.2)TVCL=TVCL*THETA(5) 
IF(CNTR.EQ.3)TVCL=TVCL*THETA(6) 
TVCL=TVCL*(AGE/50)**THETA(7) 
IF(CACB.EQ.1)TVCL=TVCL*THETA(8) 
 
 CL=TVCL*EXP(ETA(1)) 
CLML=CL*1000 
 
CSS=RATE/CL  
F=CSS 
Y = F + ERR(1) 
 IPRED=F 
  
$EST METHOD=1 INTERACTION PRINT=5 MAX=9999 SIG=2 MSFO=064B.MSF  
$THETA  
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  (0,30) ;[CL] 
  (0,1) ;[CL] 
  (0,1) ;[CL] 
  (0,1) ;[CL] 
  (0,1) ;[CL] 
  (0,1) ;[CL] 
  (-1,0.1) ;[CL] 
  (0,1) ;[CL] 
 
$OMEGA 
  0.5 ;[P] omega(1,1) 
 
$SIGMA 
  0.5 ;[A] sigma(1,1) 
 
$COV 
$TABLE ID CL CLML DAY WT AGE SEX IPRED CWRES APOD BPOD CPOD 
ONEHEADER NOPRINT FILE=064B.tab 
$TABLE ID CLML FIRSTONLY NOAPPEND NOPRINT FILE=064B.par 
$TABLE ID ETA1 FIRSTONLY NOAPPEND NOPRINT FILE=064B.eta 
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Chapter IV: R code for carrying out the GAM repetitions 
 
setwd("C:/Documents and Settings/Chaitali/Desktop/Sim_IV") 
library(nlme) 
 rm(list=ls()) 
 
####read in file that contains covariates and post-hoc estimates from NONMEM model 
df.test1 <- read.csv(file="SIM1.csv") 
 
######Gead in the covariates that you want to run the gam on (100 SNPs in our 
example) 
gam.cov <- c("G1","G2","G3","G4","G5","G6","G7","G8","G9","G10","G11","G12", 
"G13","G14","G15","G16","G17","G18","G19","G20","G21","G22","G23","G24","G25
","G26","G27","G28","G29","G30", "G31", "G32", "G33", "G34", "G35", "G36", 
"G37","G38","G39","G40","G41","G42","G43","G44","G45","G46","G47","G48", 
"G49","G50","G51","G52","G53","G54","G55","G56","G57","G58","G59", 
"G60","G61","G62","G63","G64","G65","G66","G67","G68","G69","G70", 
"G71","G72","G73","G74","G75","G76","G77","G78","G79","G80","G81", 
"G82","G83","G84","G85","G86","G87","G88","G89","G90","G91","G92", 
"G93","G94","G95","G96","G97","G98","G99","G100") 
 
n.gam.cov <- length(gam.cov) 
run <- "iter_1" 
 
###Open the gam library 
library(gam) 
 
###iter size: Group size  
###n.iter: Number of GAM repetitions 
list.iter.size <- c(25) 
list.n.iter <- c(500) 
 
runs <- list() 
 
for(i in list.iter.size) { 
  for(j in list.n.iter) { 
    runs[[length(runs)+1]] <- list( 
      iter.size=i, 
      n.iter=j, 
      results.file=paste(run,"gam",i,j,"r", sep='.'), 
      summary.file=paste(run,"gam",i,j,"r","csv", sep='.') 
      ) 
     } 
  } 
 
#### Run the GAM on CL or delta CL 
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df.fact <- as.data.frame(mapply(df.test1[,gam.cov], FUN=factor)) 
df.fact$DELC <- df.test1$CL 
gam.obj <- gam(DELC~1,data=df.fact) 
gam.iter <- function(iter.size=NULL) { 
 
  this.gam.cov <- sample(gam.cov, iter.size, replace=F) 
  scope <- lapply(this.gam.cov, FUN=function(x) { 
       eval(parse(text = paste("~", paste(c(1,x), collapse="+")))) 
  } 
  ) 
  names(scope) <- this.gam.cov 
  step.gam.obj <- step.gam(gam.obj, scope=scope, trace=F) 
  selected.snips <- names(step.gam.obj$xlevels) 
  list(selected = selected.snips, sampled = this.gam.cov) 
 
} 
summarize.gam.run <- function(results.file=NULL) { 
  res <- dget(file=results.file) 
 
  sampled <- lapply(res, FUN=function(x) { 
              x$sampled 
   } 
  ) 
  list.sampled <- unlist(sampled) 
 
  selected <- lapply(res, FUN=function(x) { 
              x$selected 
    } 
  ) 
  list.selected <- unlist(selected) 
 
  u.snip <- unique(list.sampled) 
 
  summ <- lapply(u.snip, FUN=function(x) { 
        n.select <- length(list.selected[list.selected==x]) 
        n.sample <- length(list.sampled[list.sampled==x]) 
        data.frame(snip=x,n.select=n.select, n.sample=n.sample, 
index=signif(n.select/n.sample, digits=3)) 
    } 
  ) 
  df.summ <- data.frame(do.call('rbind', summ)) 
  df.summ <- df.summ[order(df.summ$index,decreasing=T),] 
  df.summ 
} 
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### Do all of the GAMS of more than one group size and GAM repetition is selected 
big.run <- lapply(runs, FUN=function(this.run) { 
    start.date <- date() 
    res <- lapply(1:this.run$n.iter, FUN=function(x) { 
            gam.iter(iter.size=this.run$iter.size) 
      } 
    ) 
 
    dput(file=this.run$results.file, res) 
    end.date <- date() 
    res$start <- start.date 
    res$end <- end.date 
    res 
  } 
) 
dput(file=paste(run,"big.run","r",sep='.'), big.run) 
 
 
# Give us summarized results 
results.files <- unlist(lapply(runs, FUN=function(this.run) {this.run$results.files})) 
 
 
results <- lapply(runs, FUN=function(this.run) { 
        this.result <- summarize.gam.run(results.file=this.run$results.file) 
        write.csv(file=this.run$summary.file, this.result, row.names=F, quote=F) 
        this.result 
  } 
) 
names(results) <- results.files 
 
 
 
 
 
 
  
 
